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Despite advances in chemotherapy and radiation, surgery offers the highest disease-
free and overall survival rates for stage I and stage II lung cancer.   
Pulmonary resections can differ considerably in the amount of airway and 
parenchyma removed.  Central tumors may require a pneumonectomy, or removal of the 
entire ipsilateral lung.  Tumors that involve the airway known as the distal bronchus 
intermedius may require the removal of the lower and middle lobes of the right lung, a 
procedure known as a bilobectomy. Most early stage tumors are resected with a lobectomy, 
removing one of the natural divisions of the lung and the lymphatics that drain the lobe.  
Smaller tumors confined to a single segment can be resected with a segmentectomy.   
 
 
Figure 1: Types of pulmonary resections (Billmeier and Jaklitsch, 2011). 
 
Sleeve resections are a type of surgical procedure characterized by the resection of a 
circumferential portion (sleeve) of the bronchus with or without parenchyma. To reconstruct 
the airway anatomy, they require a subsequent circumferential bronchial or trachea-
bronchial anastomosis. For instance, an intraluminal carcinoid of the bronchus intermedius 
may be resected with the airway alone, while an endobronchial squamous cell cancer of the 
right upper lobe may require a lobectomy with a sleeve reconstruction of the right main 
bronchus to the bronchus intermedius. Tumors that also involve the adjacent pulmonary 
artery may also require a vascular sleeve resection to preserve lung tissue.   




Vascular sleeve resections are a topic unto themselves and will not be specifically 
addressed in this thesis. 
 
Figure 2: Types of sleeve resection (Artwork by Marcia Williams). 
 
The choice as to what type of lung resection is chosen for a given patient is based on 
different variables.  Some are related to the patient (comorbidities, pulmonary function tests, 
etc.) and others related to the tumor itself.  Tumor-related variables influencing the 
magnitude of surgery include: size, central versus peripheral location, relationship with 
surrounding structures, airway involvement, lymphatic drainage, or challenging anatomy.  For 
those tumors located peripherally, with no direct airway involvement, the preferred surgery 
continues to be lobectomy.  Lobectomy is offered if the measurements of the patient’s 
cardiopulmonary reserve predict that this can safely be done.  For smaller peripheral tumors, 
and especially for those patients with moderate to severe pulmonary dysfunction, segmental 
resection is gaining in popularity.  This is consistent with the Clinical Statement of The Society 
of Thoracic Surgeons Task Force on CT Screening, “the Task Force recommends the least 
parenchymal resection compatible with current diagnostic and oncologic principles 
performed through the least invasive surgical approach for the diagnosis and treatment of 
screen-detected nodules (Rocco et al., 2013)”. 
When the tumor invades the airway, after careful bronchoscopic planning, a more 
extended resection to achieve negative bronchial margins is usually required. For example, 
for tumors invading the right upper lobe orifice, extending to the right main stem bronchus, 




a pneumonectomy would be the standard option. For tumors invading the bronchus 
intermedius, a bilobectomy would be the procedure most commonly performed. Likewise, if 
the tumor is invading the left main stem bronchus, proximal to the left upper lobe, a left sided 
pneumonectomy would be the traditional surgery performed (Fuentes, 2003). 
Proceeding with these surgeries for airway invading tumors would, unfortunately, 
require the resection of a great amount of lung parenchyma, with the short and long term 
consequences related to the loss of functional alveoli (Alexiou et al., 2003).  Some patients 
who would require a pneumonectomy for tumor control would be considered unfit for 
surgery and thus prevented to have any type of resection because of the increased risk of 
perioperative mortality (D'amato et al., 2009) and long term complications (Rodríguez et al., 
2013). Sleeve resections and bronchoplasties preserve the uninvolved lung parenchyma. 
To avoid resection of an unproportioned amount of lung parenchyma to resect airway 
tumors and to mitigate the functional limitations of the patient after more extended 
procedures, bronchoplastic techniques arose as a valid alternative for tumor control and 
parenchyma preservation.  
Bronchoplastic procedures involve resections of the airway distal to the tracheal 
carina. Surrounding lung parenchyma may or may not be involved. The most common 
bronchoplastic resections are sleeve resections, which are circumferential airway resections 
that require remaining airways to be joined by end-to-end anastomosis with or without a 
vascular anastomosis. Consequently, lung parenchyma can be preserved for gas exchange. 
 





Figure 3: Bronchoplasty versus sleeve resections (Artwork by Marcia Williams). 
 
Sleeve resections were first described in 1947 (Thomas, 1956), but there were two 
milestones leading to their acceptance by the Thoracic Surgery community: the tracheal 
resection techniques developed by Hermes Grillo (Grillo, 1965) and the advances in lung 
transplant techniques (Perelman and Rabinowitsch, 1970; 1976). 
Sleeve resections, although technically more challenging, have been shown to be 
equivalent to extended resections in terms of local control and long term outcomes (Bagan 
et al., 2005).  What remains controversial is whether the rate of complications after sleeve 
resection, especially in the setting of neoadjuvant treatment, is higher when compared to 
other types of anatomic resections.  Some studies have already shown the negative impact of 
chemotherapy and radiation treatments on the bronchial blood supply and in the bronchial 
anastomotic healing (Yamamoto et al., 2000; Stamatis, 2008), while others, most of them with 
a limited number of patients included, have not confirmed a higher risk of airway 
complications in sleeve resection after neoadjuvant treatment (Milman et al., 2009). 
 
 

























The development of bronchoplastic procedures could not be understood without the 
knowledge of the evolution of the surgical approaches to the lung, as well as tracheal 
resections and transplantation techniques. Also, it is the anatomy of the bronchial tree that 
makes it possible to perform this type of operation, taking always into consideration the 
relationship of the airway with the surrounding structures. 
  
a) Development of surgical approaches to the lung 
 Although Thoracic Surgery was not recognized as an independent surgical specialty 
until World War II (Lindskog, 1957; Kittle, 2000), the development of approaches to the lung 
since the Thirteenth Century was related to treatment of trauma induced injuries (Lindskog, 
1957; Kittle, 2000). Rolandus (also known as Roland of Parma, Italy) was the first who 
described the treatment of a lung herniation in 1499, something thought to be impossible 
until that date (Lindskog, 1957; Kittle, 2000; Walcott-Sapp and Sukumar, 2016). With the 
evolution of the anatomical and technological knowledge, different approaches to the pleural 
cavity were subsequently described intermittently and rarely (American Medical and 
American Association for Thoracic, 1920; Walcott-Sapp and Sukumar, 2016). Some authors 
would just let the lung necrose and adhere to the chest wall before removing it, while others 
would ligate and excise the protruding lung (American Medical and American Association for 
Thoracic, 1920; Brunn, 1929; Lindskog, 1957; Kittle, 2000; Walcott-Sapp and Sukumar, 2016). 
In the era of tuberculosis (1400-1900s in Europe and America), the need to come up with 
newer and more effective therapies encouraged surgeons to try new approaches to the 
pleural cavity (Lilienthal, 1922; Kittle, 2000). 
It was Milton Anthony, founder of the Medical Academy of Georgia (USA), who in 1821 
is credited with performing the first resection of the chest wall to evacuate a lung abscess 
(Antony, 1824). This promptly moved other colleagues to explore the idea of thoracoplasties 
to collapse tuberculosed lungs.  Carlo Forlanini, from Pavia, was one of the biggest advocates 
for induced pneumothorax and collapse therapy in the treatment of tuberculosis (American 
Medical and American Association for Thoracic, 1920). 




Similar thoracic surgery techniques used successfully in traumatic injuries and 
tuberculosis were used in the nineteenth century by Jules Emile Pean, a French surgeon.  Pean 
performed the first lung resection for a tumor in Paris, France. He sutured the pleura to the 
lung and then removed a portion of the lung with galvanic current cautery. Afterwards, he 
applied carbolic acid dressings until the resection area was healed (Samson, 1940). 
Comparative anatomy studies revealed knowledge of the lung anatomy and 
physiology and the best techniques for ligation of the hilar structures (American Medical and 
American Association for Thoracic, 1920; Brunn, 1929; Lindskog, 1957; Kittle, 2000). Although 
mortality and the rate of complications were elevated, lung resection started to be accepted 
for the treatment of tuberculosis, as advocated by Theodore Tuffier and Eugène-Louis Doyen 
in France (Tuffier, 1891; American Medical and American Association for Thoracic, 1920; 
Doyen, 1985). 
Tuberculosis was the indication for the first reported pneumonectomy. It was in 1895 
when William Macewen performed it successfully in Glasgow, removing the entire left lung 
of a tuberculosis patient (Macewen, 1906; Kittle, 2000; Walcott-Sapp and Sukumar, 2016). 
Macewen was a Scottish surgeon. He was a pioneer in modern endotracheal 
anesthesia with orotracheal intubation and the performance of pneumonectomies.  He was 
credited with brain surgery, the development of bone graft surgery, and the surgical 
treatment of hernia. He was also noted for his early and creative use of photographs for 
documenting patients’ cases and for teaching surgery.  He led the way for the development 
of other anatomical lung resections without pneumonectomy. 
With the aspiration of contrast media into the bronchial tree, bronchiectasis could be 
diagnosed and lung resection became the operation of choice for treatment. Several 
lobectomies were reported by Thermisokles Gluck in Germany and by William Wayne Babcock 
in Philadelphia (1908) (Babcock, 1908). The 20th century brought not only advances in 
instrumentation and anesthesia, but also important changes in antisepsis. Encouraged by the 
new possibilities and outcomes, Evarts Ambrose Graham, in 1925, in Saint Louis, performed 
the first multiple-staged pneumonectomy for bronchiectasis (Graham, 1923; Graham and 
Singer, 1933). 




Surgery for bronchiectasis continued to develop.  Famous surgeons such as Rudolf 
Nissen, Robert Janes, Norman Shenstone and Edward Churchill as prominent names 
(Churchill, 1930; Shenstone and Janes, 1932; Roberts and Nelson, 1933; Nissen, 1949; 
Lindskog, 1957) debated the best approach to the hilum and the ligation of the hilar structures 
(Brunn, 1929; Samson, 1940; Lindskog, 1957; Kittle, 2000; Walcott-Sapp and Sukumar, 2016). 
Graham performed the first one stage pneumonectomy for lung cancer in 1933 
(Graham and Singer, 1933). The patient was Dr. James Gilmore, a 48-year-old obstetrician-
gynecologist from Pittsburgh, PA. The diagnosis had been made with liliodol bronchogram 
and pathology confirmed with a biopsy specimen obtained from a rigid bronchoscopy 
(Walcott-Sapp and Sukumar, 2016). Graham thought the treatment of lung cancer with 
radical pneumonectomy would be more effective than with limited resections, as had been 
shown in tumors of other organs (Graham and Singer, 1933; Kittle, 2000; Walcott-Sapp and 
Sukumar, 2016). 
By 1940, most of the technical difficulties of lobectomy and pulmonary resection were 
solved and the principle of lung tissue conservation was developed. Streptomycin was 
introduced in 1945, sparking the improvement of medical treatment of tuberculosis, and a 
subsequent decrease in surgery for tuberculosis (Sihoe, 2014). Further animal research and 
wartime surgical experience with traumatic bronchial transections facilitated the 
development of techniques for sleeve lobectomy and bronchoplastic procedures (Kittle, 
2000; Walcott-Sapp and Sukumar, 2016). 
 
History of Bronchoplastic Resections 
It was 1956 when Sir Clement Price Thomas, surgeon at the Westminster and 
Brompton hospitals in London, reported a patient in whom he had performed a 
circumferential resection of the right main bronchus for an adenoma projecting out of the 
origin of the right upper lobe bronchus (Thomas, 1956). The airway was closed by sewing the 
bronchus intermedius to the remnant of the right main bronchus.  The operation was a 
success, and the patient was soon able to resume his work as a Royal Air Force pilot in active 
flying duties (Walcott-Sapp and Sukumar, 2016). 




In 1952, Price Thomas, while taking care of a patient with bronchial stricture 
secondary to tuberculosis, performed a left upper lobe sleeve resection, managing to salvage 
the left lower lobe of his patient. He afterwards concluded ‘that when two ends of a bronchus 
are sewn together they can unite in the same way as two pieces of intestine’ (Johnston and 
Jones, 1959). 
With the good results of these operations and the fast postoperative return of the 
patients to their duties, sleeve resection also became a suitable operation for the treatment 
of carcinoma of the bronchus (Johnston and Jones, 1959). After Price Thomas’ reports, Phillip 
Allison in Oxford performed the first sleeve resection for a lung cancer (1952) (Johnston and 
Jones, 1959).  The first published report of the use of bronchoplasty, however, is owned by 
Donald Paulson and Robert Shaw in Dallas, in 1955 (Paulson and Shaw, 1955). In their report, 
they present 18 patients who underwent sleeve resection for both benign and malignant 
conditions. In this article, they were the first to advocate the idea that sleeve resection had 
the benefit of preservation of lung parenchyma over pneumonectomy, especially in those 
patients with low pulmonary reserve.  Following this report, they presented follow up articles 
(Paulson and Shaw, 1960; Deslauriers et al., 2009) demonstrating that in lung cancer patients 
bronchoplasties could be done electively, even with compromised pulmonary function 
(Deslauriers et al., 2009).  
In 1959, James Johnston and Peter Jones (Johnston and Jones, 1959) reported a cohort 
of 98 lung cancer patients previously treated by sleeve resection. In that article, after 
reviewing the results of sleeve resections done by others and those done by them, they 
concluded that bronchoplasties were a safe option and that their long-term results were 
comparable to those obtained by other types of resection such as pneumonectomy and 
lobectomy. 
As the trend to lung parenchymal preservation continued in the 1950s and 1960s, 
some technical advances were made. Grillo (Grillo, 1965), with his extensive and meticulous 
work in tracheal resection and reconstruction, led the way to better bronchial anastomoses. 
In addition, the experience with bronchial anastomoses in the development of lung 
transplantation (Perelman and Rabinowitsch, 1970; 1976) made sleeve resection and 
reconstruction part of the inventory of almost every thoracic surgeon. 




In 1983, Richard Firmin presented the experience of the Brompton Hospital, in 
London, with a series of 90 patients who underwent sleeve resections between 1964 and 
1974. The operative mortality of the series was 1 %. The most common complications were 
bronchial stenosis, which occurred in 6 % of patients. It was secondary to tumor recurrence 
in 4 % of the patients and to cicatrization in 2 %. The indication for the surgery was squamous 
cell carcinomas of the upper lobe (76/90) in most of the patients. Among patients diagnosed 
with malignancies, the 5-year survival was 71 % when the hilar lymph nodes were not affected 
by tumor and 17 % when they were involved. Their sleeve resection results were very similar 
to those results they were obtaining with pneumonectomies.  They subsequently concluded 
that sleeve resections were a more conservative approach to treat lung cancer with similar 
long-term survival results to those obtained with pneumonectomies (Firmin et al., 1983). 
In 1984 and updated in 1986, Penfield Faber from Chicago, published one of the most 
extensive series of sleeve lobectomies that has been published to date. This series included 
101 patients who underwent sleeve resections for lung cancer.  This group described 
bronchial dehiscence (treated with completion pneumonectomy), empyema and bronchial 
stenosis among the main complications encountered. Also, they concluded sleeve resections 
were suitable operations for both pulmonary compromised and non-compromised patients 
(Faber et al., 1984). In a follow up article, they increased the series to 115 sleeve resections 
and they described a 1.7 % operative mortality rate and a 5 % rate of technical failure, 
understood as anastomotic dehiscence requiring completion pneumonectomy (Jensik et al., 
1986). They concluded that sleeve resections, when technically feasible and when complete 
resection could be achieved, should be considered as the procedure of choice in patients with 
resectable lung cancer. 
The last significant series of sleeve resections was reported by Ingolf Vogt-Moykopff 
from Heidelberg, Germany (Vogt-Moykopf et al., 1986). In this report, published in 1986, the 
authors included 248 sleeve procedures, both bronchoplastic and angioplastic resections in 
lung cancer patients. When the resection was complete, the five-year survival rate of early 
stage lung cancer patients was 35 % and the perioperative (30-day mortality) rate was 9 % in 
bronchial sleeve resection and 5 % in combined bronchial and vascular sleeve resections. With 
these results, the authors concluded sleeve resections should be done more liberally, 
especially in lung cancer patients.  




As the history of lung resections shows, since the initial days of pneumonectomy, the 
field of thoracic surgery has advanced considerably. In the current days, the performance of 
pneumonectomies has been significantly reduced in favor of other types of lung sparing 
resections, but it remains a suitable operation for centrally located or locally advanced tumors 
in carefully selected surgical candidates.  
Pneumonectomy remains associated with high complication rates, especially for 
patients with limited pulmonary function. With these considerations in mind, bronchoplastic 
procedures were introduced as alternatives to pneumonectomy for patients with disease 
involving proximal bronchi (Paulson and Shaw, 1960). 
Although initial indications for sleeve resections were for lung parenchyma-sparing 
purposes and for limited respiratory function candidates (Wain, 1998; Ma et al., 2007), the 
truth is that sleeve lobectomy has become accepted for anatomically suitable tumors, 
regardless of pulmonary function. 
 
Differences between bronchoplasty and sleeve resection 
Bronchoplasty refers to any procedure that involves bronchial reconstruction or 
anastomosis to restore the bronchial lumen anatomy. The most commonly performed 
bronchoplasty is sleeve resection, but it can be performed after wedge resection of the airway 
(Narendra and Schmidt, 2018). They don’t necessarily involve circumferential reconstruction 
or anastomosis of the airway as sleeve resections do.  
Bronchoplasties have had an important role in the management of both benign and 
malignant conditions of the airway, allowing for maximum preservation of lung parenchyma 
(Bueno et al., 1996; Jalal and Jeyasingham, 2000). The most commonly used bronchoplastic 
technique; however, is the sleeve resection (End et al., 2000; Nagayasu et al., 2015). 
 
b) Indications for sleeve lobectomy 
Sleeve lobectomy is most commonly indicated for lesions involving main or lobar 
bronchi (Tronc F, 2008). These lesions typically are benign to low-grade malignant neoplasms 
and stenosis (Wain, 1998). Carcinoid tumors are the most common low-grade neoplasm 




treated with sleeve resection.  They account for more than 80 % of reported sleeves, followed 
by mucoepidermoid tumors, fibrous histiocytomas, hamartomas and adenoid cystic 
carcinomas (Wain, 1998). Most strictures involve traumatic or post-infectious etiologies. 
Sleeve lobectomy for bronchogenic carcinomas is less common, and is performed in less than 
10 % of operable cases of lung cancers. In addition to the anatomic location, a sleeve 
lobectomy has a role when the bronchial resection margin is at risk of being affected by the 
tumor or in the case of peri-bronchial lymph node involvement (Wain, 1998). Sleeve 
lobectomy is also indicated for patients with impaired cardiopulmonary function (Suzuki et 
al., 2000). 
General indications for sleeve resection as a lung parenchyma sparing procedure 
include FEV1 < 50 % predicted value and DLCO < 50 % predicted value (Wain, 1998). 
Any lobe can be resected with a sleeve resection; however, the most commonly 
performed operation is the right upper lobe sleeve resection (Suzuki et al., 2000; Wright, 
2006). The explanation lies in the anatomy of the right mainstem bronchus and its anatomic 
relation to the long bronchus intermedius (Wain, 1998; Tronc F, 2008). The left upper lobe is 
the second most common site for sleeve lobectomy. A left upper lobe sleeve resection is 
technically more challenging due to presence of the aorta and left recurrent nerve (Wain, 
1998; Tronc F, 2008). 
 
c) Contraindications of sleeve lobectomy 
Patients with advanced lung cancer, specifically T4 disease, are typically poor 
candidates for sleeve lobectomy. Involvement of the pleura, superior vena cava, atria, or 
transverse aortic arch are also considered contraindications (Faber, 1995). Relative 
contraindications include invasion of the pericardium, phrenic nerve, vagus nerve, and 
diaphragm (Faber, 1995). The presence of N1 or N2 nodal disease does not contraindicate 
sleeve lobectomy, but N2 significantly impairs long-term outcomes due to its association with 
systemic recurrences (Mehran et al., 1994; Terzi et al., 2002; Kim et al., 2005; Yildizeli et al., 
2007; Schirren et al., 2011; Berry et al., 2014). Sleeves are generally performed in this setting 
when, in order to achieve an appropriate oncologic resection, the alternative is a 
pneumonectomy. If the patient is diagnosed with N2 nodal disease and it is not clear if he/she 




would tolerate a more extended resection than a bronchoplasty, definitive medical treatment 
should be carefully considered. 
 
d) Patient selection for sleeve resection 
Flexible bronchoscopy is the most important diagnostic step in identifying potential 
candidates for sleeve lobectomy (Wain, 1998). The key finding is endobronchial tumor 
extension from segmental bronchi to the lobar or main bronchial orifice (Tronc F, 2008). 
Bronchoscopy also allows for tissue biopsy, which is particularly important if a malignancy is 
suspected (Faber, 1995). Mucosal biopsy both proximal and distal to the lesion should be 
attempted to assess tumor extension when feasible (Faber, 1995). Detection of decreased 
bronchial wall motion during respiration may be a sign of peri-bronchial tumor infiltration, 
and this requires further radiographic evaluation to assess for tumor extent and its 
relationship to the airway (Rendina et al., 2002). Radiographic studies play a supplemental 
role to bronchoscopy in identifying potential surgical candidates. Computed tomography (CT) 
allows for better appreciation of disease size, extent, and location relative to mediastinal and 
thoracic structures (Tronc F, 2008). Magnetic resonance imaging (MRI) can help 
interpretation of ambiguous CT findings. If suspicious mediastinal lymph nodes are identified, 
further investigation via PET, EBUS or mediastinoscopy is warranted as N2 disease may 
indicate the need for pneumonectomy or neoadjuvant treatment (Faber, 1995; Yildizeli et al., 
2007; Deslauriers et al., 2009). General pre-operative considerations for other pulmonary 
resections should also be considered for sleeve lobectomy candidates. 
 
e) Anatomy of the airway 
The lung is a complex anatomic structure, isolated by the visceral pleura from the 
surrounding structures but intimately related to them. An organizational outline of the 
anatomy of the lung can be helpful: 
 Anatomy of the airway is sub-divided into: 
o The proximal airway, including the supraglottic, glottis and infraglottic areas.  
This portion of the airway is outside the focus of this thesis. 




o The distal airway, which includes the trachea, the mainstem bronchi and 
multiple bronchial divisions (Tsuchiya, 2008). 
 
 Trachea: The trachea is a cartilaginous and fibromuscular structure 
extending from the cricoid cartilage (located approximately at the level of 
the sixth cervical vertebra) to the carina (located at the level of the fifth 
thoracic vertebra). Its length varies depending on the age of the patients. 
It ranges from 3 cm at birth to up to 10-12 cm in adults (one third is extra 
thoracic in the throat, and two thirds are intrathoracic). The tracheal 
diameter is also variable, and it goes from 13 to 25 mm in males to 10 to 
21 mm in females (Grillo, 1965).The trachea consists of 4 different layers: 
the mucosa, the submucosa, the cartilage in the front or smooth muscle in 
the posterior wall, and the adventitia.  
 Bronchi: The bronchi can be divided into two types:  extrapulmonary 
(outside the pleural envelope) and intrapulmonary (inside the pleural 
envelope) (Tsuchiya, 2008). Both mainstem bronchi and the bronchus 
intermedius are extrapulmonary, with important dissection implications. 
They are structurally similar to the trachea, with horse-shoe shaped 
cartilaginous rings and a posterior membranous portion.  The 
intrapulmonary bronchi have a less clear structure than the 
extrapulmonary ones. They consist of irregularly shaped cartilage plates 
distributed around the bronchus in a paving stone configuration (Tsuchiya, 
2008).These differences should be considered when reconstructing the 
airway, as failure to do so would have important consequences in the 
creation of the anastomosis. Shape mismatch is another important factor 
to consider when suturing the two bronchial edges together (Hollaus et al., 
2001). 
 





Figure 4: Differences between extrapulmonary airway (A) and 
intrapulmonary airway (B). (Artwork by Marcia Williams). 
 
 The vascular supply to the trachea and bronchi is characterized by a wide 
variability (Tsuchiya, 2008). It is important to know these variations as 
every effort to preserve this vasculature should be made, especially in 
sleeve resections. The bronchial blood supply depends on branches arising 
from the inferior thyroid arteries, the intercostal arteries, and the 
bronchial arteries. These arteries, except for the branches of the thyroid 
artery, tend to form a very rich vascular anastomosis in the subcarinal area. 
This peri-bronchial plexus follows the bronchi into the lung parenchyma 
and supplies blood to the visceral pleura and the walls of the pulmonary 
arteries and veins (vasa vasorum). 
Bronchial arteries originate from the thoracic aorta, at the level of 
T5 and T6 (Walker et al., 2015). The left bronchial arteries normally arise 
directly from the aorta. Right bronchial arteries can originate from the 
aorta, but most of the time, they share a common origin with another 
artery, normally an intercostal artery (Morita et al., 2010). The most 
frequent pattern is a shared origin of the right bronchial artery and an 
intercostal artery (52 % of cases at CT angiography), a finding known as a 




common intercostal-bronchial artery trunk. This trunk tends to originate 
from the anteromedial or posteromedial thoracic aortic wall and runs 
superiorly, giving one or more intercostal arteries before continuing 
inferiorly as the bronchial artery (Cauldwell and Siekert, 1948; Pump, 1963; 
Morita et al., 2010; Ziyawudong et al., 2012).Less frequently, the left and 
right bronchial arteries share a common origin (32 % of right and 36 % of 
left bronchial arteries at CT angiography), a finding known as the common 
trunk of both bronchial arteries. The common trunk of both bronchial 
arteries normally originates from the anterior-lateral thoracic aortic wall 
(Morita et al., 2010).  
A study performed in 150 cadavers described up to nine types of 
variations in bronchial artery anatomy (Cauldwell and Siekert, 1948). The 
most common variation, type 1 (40.6 % of cases), consisted of one right 
bronchial artery arising from a common intercostal-bronchial artery trunk 
and two left bronchial arteries. Type 2 was the second most common 
pattern (21.3 %), consisting of a single bronchial artery on each side, with 
the right bronchial artery originating from a common intercostal-bronchial 
artery trunk. Type 3 was the third most common pattern (20.6 %), 
consisting of two bronchial arteries on each side, with one of the right 
bronchial arteries originating from a common intercostal-bronchial artery 
trunk. Types 4–9 were other variations of bronchial arteries, with up to four 
arteries on each side. Although type 1 was the most common anatomic 
pattern in the original study (Cauldwell and Siekert, 1948), other authors 
have reported type 3 to be the most common variant (Liebow, 1965; Kasai 
and Chiba, 1979). 
 
 Lung parenchyma: It is composed of five lobes divided into 19 segments and its main 
function is the gas exchange at the alveolar level. 
Both lungs are divided into lobes. Each lobe is also divided into segments.  The 
segments are an important unit of the lung for the close relationship they have with 
the segmental bronchi. The right lung consists of 10 segments: 3 located in the right 
upper lobe (apical, anterior and posterior), 2 forming the right middle lobe (medial 




and lateral), and 5 in the right lower lobe (superior, basilar medial, basilar anterior, 
basilar lateral, and basilar posterior). The left lung is formed by 9 segments: 4 located 
in the left upper lobe (apical, posterior, anterior, and lingula) and 5 in the left lower 
lobe (superior, basilar anterior, basilar medial, basilar lateral, and basilar posterior). 
The lungs are surrounded by the intimately attached visceral pleura.  In the 
absence of effusion or pneumothorax, the visceral pleura is in contact with the parietal 
pleura and the lateral surface of the mediastinum. The visceral pleura invaginates into 
the lungs to form the intra-lobar fissures. There is one minor and one major fissure in 
the right lung and one major fissure in the left lung. The pleura also forms the inferior 
pulmonary ligament, which extends inferiorly along the mediastinum from the inferior 
pulmonary vein to the diaphragm. 
 
 Pulmonary vasculature: There is a close relationship with the bronchus and the 
pulmonary vessels. These consist of the pulmonary arteries and veins. The pulmonary 
artery arises from the right ventricle and divides into 2 branches. The right pulmonary 
artery runs posterior to the aorta and the superior vena cava.  It lies anterior to the 
right tracheobronchial angle, lateral to the atria and anterior and inferior to the right 
mainstem bronchus. It gives branches that supply the upper lobe and runs anterior to 
the bronchus intermedius. The left pulmonary artery originates anterior to the left 
mainstem bronchus and the secondary carina. These are important spatial 
relationships when planning the surgical approach and the extent of the resection 
(Tsuchiya, 2008).  
 
f) Surgical technique 
The standard approach for sleeve lobectomy is through a posterolateral thoracotomy 
or a muscle-sparing anterolateral incision (Faber, 1995; Nagayasu et al., 2015). Once the chest 
has been opened, pre-operative assessment should be conducted by visualization and 
palpation of the hilum, lung parenchyma, pleural surfaces, lymph nodes, and other 
surrounding structures.  Specifically, M1a disease with pleural carcinomatosis or bulky disease 
at the hilum requiring pneumonectomy would preclude sleeve resection. If no 
contraindications are encountered, mobilization of the lobe should be started. 




The surgery begins at the hilum with a circumferential cut of the visceral pleural 
reflection onto the mediastinal pleura.  This includes mobilization of the inferior pulmonary 
ligament.  This is followed by careful dissection of the superior and inferior pulmonary veins 
to isolate them from surrounding structures.  Furthermore, the superior pulmonary vein is 
dissected more distally to clearly identify the upper lobe venous branches from the right 
middle lobe vein.  Prior to division of the venous branches, the pulmonary artery trunk and 
distal lobar and segmental branches are comfortably dissected from the nodal tissue and 
identified.  Dissection should be carried out carefully preserving the bronchial vessels that will 
supply the remaining distal lung parenchyma. Once lobar arterial supply has been adequately 
identified and transected, the corresponding pulmonary veins should similarly be divided. 
Incomplete fissures should be divided at this time as well.   
Once the hilar structures have been mobilized, and the final decision has been made 
in favor of a sleeve resection, then the vascular structures are divided.  Generally, we prefer 
to divide the venous drainage of the lobe first, which then further exposes the slightly more 
posterior arterial branches.  The arterial branches are then divided, fully exposing the 
bronchial structures. 
Airway dissection and transection should be completed only after the rest of the hilar 
structures have been divided. Most anastomotic complications result from disruption of 
mucosal blood flow to the bronchi; therefore, careful consideration should be given to the 
bronchial blood supply which is located within the peri-bronchial tissue. Unnecessary lymph 
node dissection should be avoided when possible, as this may also compromise bronchial 
blood supply. The presence of a single right bronchial artery makes these considerations 
particularly important when performing right sided sleeve lobectomies.  To preserve the 
bronchial artery blood supply, the proximal bronchi should be circumferentially divided with 
a sharp knife close to the origin of the main bronchus. 
 Although the anatomy of the bronchial arteries varies considerably, at this point it is 
possible to identify and try to preserve those arteries.  
Most commonly, bronchial arteries on the right run both posteriorly and anteriorly in 
the tracheobronchial angle.  On the left, they run posterior to the membranous part of the 
mainstem bronchus. They tend to bifurcate and to form a plexus that connects to both the 
pulmonary arterial tree and branches of the other bronchial arteries.  Thus, the bronchial 




arteries connect to both the pulmonary vasculature system and the systemic system.  It is this 
phenomenon that allows lung transplantation without re-implantation of the bronchial 
arteries.  The transplanted lung allograft obtains perfusion of the donor airway through 
reverse flow from the pulmonary vasculature to the donor bronchial arteries.   
 
Figure 5: Bronchial arteries anatomy (Riquet, 2007). 
Distal bronchotomy should be made in a similar fashion at the level of the segmental 
bronchi, which is the location of a rich pulmonary and systemic arteriolar anastomoses. 
Frozen histological evaluation of bronchial resection margins is recommended before 
performing the final anastomosis. Tumor-free margins of at least 5 mm for high-grade 
carcinomas and 3 mm for low-grade lesions are considered minimal requirements. If these 
margins cannot be obtained, a more extended pulmonary resection should be performed 
(Wain, 1998). Carcinoma in situ and less severe forms of dysplasia at the margins, however, 
do not require additional resection, as these findings have not been associated with higher 
recurrence rates (Wain, 1998). 
The proximal and distal airways should be anastomosed in an end-to-end fashion. The 
anastomosis should be completed under minimal tension and with minimal luminal size 




mismatch.  If these goals are achieved, there is no limit in regard to the maximum distance 
that can be anastomosed.  The maximal distance of a sleeve resection is a right lower lobe to 
the proximal right main bronchus (about 5 cm) or the left lower lobe back to the left main 
bronchus (5 to 7 cm). Tension can be typically minimized releasing the inferior pulmonary 
ligament. When further mobilization is necessary, an infrahilar pericardial release may be 
performed by dividing the pericardium below the inferior border of the inferior pulmonary 
vein in a U-shaped cut (Figure 6)(Wright, 2006; Wadell and Uy, 2015). 
 
Figure 6: Pericardial release (Wadell and Uy, 2015). 
 
Most surgeons perform the bronchial anastomosis in an interrupted fashion, however, 
an uninterrupted technique is also acceptable (Bayram et al., 2007; Palade et al., 2015). Short 
and long-term results are comparable in both human series (Kutlu and Goldstraw, 1999; 
Bayram et al., 2007) and canine models (Lowson, 1893). If possible, the use of a layer-to layer 
orientation, sewing membranous portion to membranous portion and cartilaginous portion 
to cartilaginous portion, should be utilized as it minimizes potential inconsistencies in luminal 
architecture (Hollaus et al., 2001).  Furthermore, it prevents kinking of the distal airway with 
subsequent retained secretions in the postoperative period. 




Ideally, the anastomosis should be begun in the region most difficult to visualize. Most 
authors use sutures at both ends of the airway where the posterior membrane meets the 
bronchus to align the rings. These traction sutures should be placed both in the proximal and 
distal transected airway not only to prevent torsion and mal-positioning but also to release 
further tension in the remaining suture line. Absorbable 3-0 or 4–0 sutures (polyglactin or 
VicrylTM) are traditionally used  since the recommendation by Dr. Hermes Grillo (Grillo, 1965).  
The knots are placed outside the bronchial lumen.  This suture is chosen to decrease the rate 
of stricture and granuloma formation (Wright, 2006). On the other hand, if a continuous 
suture is preferred, polydioxanone (PDSTM) or polypropylene (ProleneTM) monofilament 
sutures are also broadly used (Kutlu and Goldstraw, 1999; Palade et al., 2015).  
To account for discrepancies in bronchial lumen diameter, there are several 
techniques that can be utilized. One relatively simple approach is the application of space-
suturing to stretch the smaller lumen to better approximate the larger (Wright, 2006). Other 
methods include the excision of a small wedge of tissue and plication of the larger bronchus 
(Bayram et al., 2007) or telescoping techniques. Telescoping techniques should be reserved 
for scenarios in which significant mismatch exists among diameters between proximal and 
distal bronchi (Hollaus et al., 2001). The primary limitation in telescoping methods is the 
remaining shelf of bronchial tissue, which tends to protrude into the bronchial lumen. This 
tissue may necrose or serve as a focus for secretion retention or infection.  
When possible, the anastomosis should be covered with pedicled tissue to prevent 
bronchopleural and bronchovascular fistula formation. The use of pedicled tissue is also 
thought to aide in the formation of systemic blood flow to the anastomosis (Klepetko et al., 
1999). Easily mobilized pedicled tissues include intercostal muscle flaps or pericardial fat 
pads.  
Special care in preparing and handling the flaps should be focused on preserving their 
blood supply.  The pedicle is the intercostal artery and vein for intercostal muscle flaps.  The 
pedicle is the superior or middle branch of the pericardial-phrenic artery for upper pericardial 
fat pads or the musculophrenic branches of the internal mammary artery in the case of an 
inferior pericardial fat pad (Anderson and Miller, 1995). Alternate options include the thymus 
(whose arterial blood supply arises from the internal thoracic artery and the inferior thyroid 
arteries and the venous drainage is by the thymic vein to the innominate vein) (Raj and Pillay, 




2015), omentum (vascularized by the gastroepiploic artery that is on the same side as the lung 
resection) (Mathisen et al., 1988; Khaghani et al., 1994; Boulton and Force, 2010), and pleura 
(Wright, 2006). 
Before closing the chest, it is recommended to perform surveillance flexible 
bronchoscopy to evaluate for luminal continuity at the anastomosis. Even the slightest 
mucosal inconsistencies predispose for stricture formation (Tronc F, 2008). All residual 
secretions and blood should also be removed from the airway at the time of final 
bronchoscopy (Tronc F, 2008). 
Although sleeve lobectomy and bronchoplastic procedures have traditionally been 
performed through a posterolateral thoracotomy, some authors have described its feasibility 
by minimally invasive approaches or VATS (Video-Assisted Thoracic Surgery) (Mahtabifard et 
al., 2008; Gonzalez-Rivas et al., 2013; Zhou et al., 2015; Ma and Liu, 2016) and RATS (Robot-
Assisted Thoracic Surgery) (Cerfolio, 2016; Lin et al., 2016; Pan et al., 2016; Gu et al., 2017). 
The number of reports of minimally invasive sleeve resection in the literature is 
growing. The largest series was published by Zhou et al (Zhou et al., 2015) in 2015. In that 
study, including 10 sleeve resection patients, the authors concluded that sleeve resection 
could be performed safely by VATS with similar short and long-term results when compared 
to thoracotomy.  
In 2016, Robert Cerfolio (Cerfolio, 2016) reported the early results of 8 patients who 
underwent RATS sleeve resection, with no 30 or 90-day mortality and without bronchial 
anastomosis complications at 6 months.  He concluded it was a feasible and safe alternative 
to thoracotomy in experienced hands.  
In that year, too, Pan et al (Pan et al., 2016) reported 21 cases of robotic sleeve 
resections, both bronchial and vascular.  Although it was an initial experience, they concluded 









g) Types of sleeve resections and specific considerations 
 
1. Right upper lobe sleeve resection (Mentzer et al., 1993; Mentzer, 1998; Ibrahim et al., 
2013): 
This sleeve resection can be performed either through a lateral (4th rib interspace) 
or through a posterolateral thoracotomy (5th rib interspace), given the anatomy of the 
right upper lobe bronchus. The dissection in these cases must be carefully planned and 
completed. Once in the chest, a detailed and complete exploration should be made, 
including the chest wall and the entire lung surface. In case any signs of metastatic disease 
are encountered, there would be no indication for proceeding with the sleeve resection.  
Next, the hilum is addressed, and the pulmonary artery is dissected out and isolated.  A 
right-angle clamp or other type of dissector should be easily placed behind the artery, and 
a vascular loop or cord tape is passed around it. 
The pulmonary artery dissection is an important step.  If careful and complete 
dissection is not achieved, the next steps will become more difficult and unsafe. If any 
concern exists regarding the ability to obtain good proximal control of the artery, we 
recommend opening the pericardium and obtain control of the proximal right pulmonary 
artery just lateral to the superior vena cava. 
Afterwards, the main-stem bronchus and the right upper lobe bronchus should be 
dissected free from the surrounding structures. Where the right upper lobe bronchus and 
the bronchus intermedius bifurcate lays the sump node. This node drains all three lobes 
of the right lung.  Removing this node will open the field for subsequent dissection of the 
bronchus intermedius. Running medial and inferior to this node is the superior segmental 
branch of the pulmonary artery.  
The right upper lobe vein is ligated. The ascending truncus branch of the 
pulmonary artery is ligated. The fissure can be completed at this point with sequential 
firings of the stapler. The remaining posterior recurrent segmental branch of the 
pulmonary artery can be transected.  
Now, the mainstem bronchus is sharply divided proximal to the takeoff of the right 
upper lobe bronchus. It is of crucial importance that division of the airway is perpendicular 
to its long axis. Failure to do so will result in a more difficult anastomosis later. In a similar 
way, the bronchus intermedius is divided just distally to the right upper lobe takeoff.  




Different techniques and tricks have been used to achieve the best possible 
perpendicular cut, from placing the knife blade in a right-angle clamp, to starting the cut 
with the knife and finishing it with Metzembaum scissors, to assure the desired angle is 
achieved. 
Frozen-section margins are mandatory, as they will determine if there is a need 
for further airway resection, including a possible conversion to a pneumonectomy. If the 
distal margin is positive for tumor, expanding the resection to include the middle lobe, or 
middle lobe and superior segmental bronchus while preserving at least the basilar 
branches to the right lower lobe bronchus may allow the surgeon to perform a 
bilobectomy instead of a pneumonectomy. If it is the proximal margin that is positive for 
tumor on frozen section, a resection of the carina with anastomosis of the right middle 
and lower lobes can be considered. 
After assuring appropriate negative margins, the anastomosis of the two edges of 
the bronchus is performed. The remaining right mainstem bronchus is reunited with the 
bronchus intermedius. It is essential that the anastomosis is performed under no tension, 
and careful attention should be paid to avoid torsion or kinking of the reconstructed 
bronchus.  To assure no tension of the anastomosis, several maneuvers have been 
described. These include, systematically releasing the inferior pulmonary ligament.  When 
tension is still present, dissection of the subcarinal and paratracheal area will gain some 
proximal relaxation to perform the anastomosis. In case tension is still observed, an 
infrahilar pericardial release (previously described) can be performed to try to bring the 
edges together without force.  
Because of the different calibers of the mainstem bronchus and the bronchus 
intermedius, the size discrepancy between them should be corrected with careful suture 
placement. Both interrupted and running techniques offer good results, and the choice of 
one or the other depends mostly on the surgeon’s preferences.  The distance of the 
sutures in one bronchial side should be the same as that in the other if the airways are 
approximately the same size.  A good rule to follow is to place the sutures 2 to 3 mm apart 
and 2 to 3 mm back from the cut edge of the bronchus.  If the airways do not match in 
size, placement of the sutures closer on the smaller bronchus and slightly further apart on 
the larger bronchus can correct the size discrepancies and assure an air-tight anastomosis. 




After the anastomosis is completed, it is checked under water or saline (as this 
allows visibility of an air leak) and a Valsalva maneuver is performed by the 
anesthesiologist. If no air leak is detected, the authors proceed with placement of a 
buttress to the airway anastomosis.   
Reinforcement of the anastomosis with a flap to provide a source of new 
vasculature to facilitate healing is controversial, though some surgeons do it routinely. 
This flap is not intended to produce a tight anastomosis, but to provide a source of 
vasculature to facilitate healing of the partly devascularized bronchus and prevent its 
breakdown and separate the nearby pulmonary artery from the bronchus. Pleural, 
mediastinal or azygous vein flaps can be used, based on the surgeon’s choice.  Finally, the 
chest tube is left in place and the incision is closed. I highly recommend postoperative 
bronchoscopy at the end of the procedure to clear retained secretions distal to the 
anastomosis.  Most patients can be extubated in the operating room. 
 
2. Right middle lobe sleeve resection (Mentzer et al., 1993; Isbell and Jones, 2011): 
As noted, the right upper lobe sleeve resection is the classically described 
procedure. A right-middle-lobe sleeve resection is uncommon for the technical challenges 
it carries. The technique is similar to that described for the right upper lobe sleeve 
resection but with the attention centered in the middle lobe vasculature and airway 
structures. However, it should be noted that in all the described resections, proximal 
control of the arterial blood supply is essential.  Accordingly, isolation of the pulmonary 
artery descending truncus is performed in almost all cases. 
The challenges of the right middle lobe sleeve resection are secondary to the 
anatomical relationships of its airway and its blood supply. In the middle lobe, the vein is 
anterior to the airway, and the pulmonary artery branches are located behind the 
bronchus. This makes the vasculature less accessible. Also, division of the distal airway is 
a critical step because the superior segment bronchus arises just opposite to the middle 
lobe bronchus.  It may be difficult to preserve the superior segmental bronchus if the 
appropriate angle of division of the airway is not achieved. The transection of the proximal 
bronchus intermedius needs to be angled too, because failure to do so will prevent a well 
size-matched anastomosis. Due to this airway caliber mismatch, the right middle lobe 
sleeve resection has been considered technically more challenging than other resections, 




leading in multiple occasions to a right lower bilobectomy with preservation of the right 
upper lobe. 
 
3. Left upper lobe sleeve resection (Mentzer et al., 1993; Sundaresan, 1998; Isbell and 
Jones, 2011): 
As with the right-sided resection, proximal control of the pulmonary artery is 
obtained first. The anatomic characteristics of the pulmonary artery on the left side, being 
shorter, with an early takeoff of the anterior segmental branch and running around the 
left mainstem bronchus may make proximal control more challenging.  
Most of the steps are similar to the right upper lobe sleeve resection. First, the 
posterior aspect of the fissure is completed with a stapler and all the anatomic structures 
are identified. It is critical at this point to avoid injuring the superior segmental branch of 
the pulmonary artery, which runs in this area. The vein and the artery branches are 
divided. The bronchus is divided proximally and distally to the takeoff of the left upper 
lobe bronchus.  
Special care is needed in the distal airway division, because the superior segmental 
bronchus takeoff occurs a short distance from the left upper lobe bronchus takeoff. A tape 
around the bronchus helps to delineate these relationships.  The rest of the steps are 
performed as previously described. 
 
4. Left lower lobe sleeve resection (Gonzalez-Rivas et al., 2013; Galetta and Spaggiari, 
2017): 
This is one of the most technically challenging sleeve resections given the 
particular relationship of the left mainstem bronchus and the pulmonary artery.  
The first step is to divide the inferior pulmonary ligament and the posterior 
mediastinal pleura to gain access to the posterior hilum.  Circumferential divisions of the 
visceral pleural to mediastinal pleural reflection is helpful to free up all of the hilum.  The 
pulmonary artery is identified, dissected and controlled at the fissure. The superior 
segmental and basilar segmental branches of the pulmonary artery can be stapled at this 
point. Lymph node dissection of the subcarinal space will greatly help in order to gain 
proximal control of the airway. The airway needs to be transected proximally and distally 
following the principles stated above. Special attention should be given to the retraction 




of the pulmonary artery to the upper lobe when performing the anastomosis, as the artery 
and the pericardium can obstruct the field.  
 
5. Proximal airway resection (carina and distal trachea) (Grillo, 1965): 
Performing a resection of the proximal airway (carina and distal trachea), always 
requires a sleeve resection. To begin resection of the distal trachea or carina, a 
bronchoscopy is routinely performed to help surgical planning. 
The incisions described have been multiple, from sternotomy to left and right 
sided posterolateral thoracotomies, but all of them aim to provide the best possible 
surgical field to obtain a tension free anastomosis. 
Again, achieving good exposure and careful dissection of all the anatomic 
structures becomes mandatory for a successful resection. On the left side, this begins with 
mobilization of the left pulmonary artery and aortic arch. The ligamentum arteriosum can 
be divided and this greatly improves the visualization of the carina and distal trachea.  
Special attention is required to identify and preserve the recurrent laryngeal nerve.  On 
the right side, the surgical approach begins with the dissection of the carina and 
mobilization of the right pulmonary artery and bronchus. 
Because of the delicate vascular supply to the distal trachea, careful mobilization 
must be done while preserving the small vessels in the trachea-esophageal groove.  Just 
the necessary portion of the airway should be dissected. Normally, this is 3 to 4 mm 
around the pretracheal space, where division of the trachea takes place.  
Of note, traditional single-lung ventilation is challenging once the airway has been 
transected. To facilitate continued ventilation, a sterile circuit, with an armored 
endotracheal tube, is passed onto the field. Operative planning is crucial at this time, as 
communication with the anesthesia team should be close and clear. The JET ventilator can 
be used, too, but there are several disadvantages to its use. First of all, as the airway is 
open, it is not possible to stablish positive end expiratory pressure (PEEP), making difficult 
to ventilate obese patients or patients with reduced pulmonary compliance (Biro, 2010). 
Likewise, it is not possible to measure appropriately the peak inspiratory pressure and 
end-tidal carbon dioxide, leading to hypercapnia, dynamic hyperinflation, barotrauma and 
hypothermia (Young, 1989; Myles et al., 1997; Fernandez-Bustamante et al., 2006). 




  There is a growing experience of using Extra-Corporeal Membrane Oxygenation 
(ECMO) support during this portion of the operation with an open airway.   
The most commonly performed proximal airway procedure is the resection of the 
left main bronchus without lung tissue removal, and anastomosis of the distal trachea to 
the left main bronchus in an end-to-end fashion. The same anastomotic principles that we 
have previously described under the right upper lobe sleeve resection apply to this 
operation, as well.  The right lung is included in the airway again with an end-to-side 
anastomosis. This anastomosis can be performed to the distal trachea or to the left 
mainstem bronchus (depending on available length), in a tension-free manner. 
This anastomosis is performed in a similar interrupted suture fashion, generally 
with 3-0 Vicryltm. Of note, the distal tracheal transection and the proximal bronchial 
transection should be performed at the level of the cartilaginous rings to provide enough 
strength for the anastomosis. As described previously, the anastomoses are traditionally 
wrapped with a pedicled flap before closure of the chest (Figure 7).  
 
Figure 7: Latissimus dorsi pedicled muscle flap (Orgill et al., 2015). 




Role of ECMO in airway resection 
ECMO is being used with more frequency in complicated airway resections and 
reconstructions.  It allows the anesthesia team to maintain an appropriate gas exchange 
at the same time that ensures an unobstructed operative field (eliminating the need for 
cross field ventilation) and facilitates precise surgical dissection.  It is currently used for 
both ventilator and hemodynamic support in lung transplantation, airway resection and 
reconstruction and extended tumor resections (Hoetzenecker et al., 2017). 
Some authors (Hoetzenecker et al., 2017) consider ECMO pre-emptively in all 
surgical candidates with critical airway problems or resections. They use it routinely when 
complete airway occlusion or prolonged cross-field ventilation is anticipated.  The most 
important part of these complex airway reconstructions is an optimal surgical exposure 
with adequate control of the patient’s ventilation, and ECMO can facilitate both. 
There are different available configurations:  
1) Veno-venous (V-V) ECMO: It is the preferred modality for airway 
resections. It offers complete pulmonary function support with 
appropriate CO2 exchange and oxygenation. Its main advantage when 
compared to veno-arterial support (V-A) is the decreased risk of 
complications related to arterial cannulation, such as bleeding, 
pseudoaneurysms, ischemia of the limbs and embolic episodes (Jacobs et 
al., 1997; Lorusso et al., 2016). The most common configuration is femoral-
jugular with two cannulas (Hoetzenecker et al., 2017). 
2) Single-cannula V-V ECMO: One of the most remarkable advances in the 
ECMO field has been the development of double-lumen cannulas that 
allow single vessel access instead of femoro-femoral or femoro-jugular 
configurations.  Increased experience with these cannulas after lung 
transplantation has allowed their introduction in airway surgery too (Reeb 
et al., 2011; Gothner et al., 2015). Its main disadvantage is that the 
placement of the cannula in the right atrium requires either fluoroscopy or 
a transesophageal echocardiogram to avoid complications such as 
perforations (Johnson et al., 2014). 
3) Veno-arterial ECMO: In contrast with V-V ECMO, it also provides 
hemodynamic support. This can become of crucial importance in 




emergencies, for example, when an airway occlusion has led to 
hemodynamic compromise. It also facilitates heart retraction and 
mobilization in complex cases of airway reconstruction. Its disadvantage is 
that it is more invasive than the V-V approach and it has been associated 
with an increased number of complications like neurological events 
(embolic episodes, infarction, and hemorrhage) and vascular complications 
(dissections, limb ischemia, aneurysms and pseudoaneurysms). Another 
important consideration is that femoro-femoral A-V ECMO sometimes is 
unable to provide adequate central oxygenation in patients with high 
cardiac output.  
 
V-V ECMO is, thus, the configuration of choice for airway resections, as it can fully 
support the patient’s ventilatory function with either one or two cannulas (Ko et al., 2015). 
For complex carinal reconstructions, a central V-A ECMO approach is preferred if 
extensive manipulation of the heart and the great vessels is required to assure adequate 
visualization (Lang et al., 2014). 
The main disadvantages that were previously reported with ECMO, such as 
bleeding and distal tumor cell spread, have been overcome by recent technological 
advances. In the new ECMO circuits, the risk of bleeding can be minimized using only 
partial heparinization (with goal activated clotting times of 160-180 seconds) and the risk 
of tumor cell spread has become negligible, as ECMO is a closed circuit and the suctioned 
products can be left unused (Hasegawa et al., 2002). 
Since 2015, when the first report of the use of ECMO in airway reconstruction at 
the Toronto General Hospital was published (Ko et al., 2015), several authors have 
assessed the utility of ECMO in complex oncologic and benign airway resections (Horita et 
al., 1996; Keeyapaj and Alfirevic, 2012; Lang et al., 2014; Wang et al., 2014). 
 
6. Lymph node dissection in sleeve resection 
Although most authors (Wain, 1998; Wright, 2006) recommend to avoid excessive 
lymph node dissection to avoid bronchial devascularization, it has been extensively 
established that there is a relationship between advance nodal status (N2 disease) and 
decreased long term survival after sleeve resection (Rea et al., 1997; Tronc et al., 2000; 




Fadel et al., 2002; Yildizeli et al., 2007; Rea et al., 2008; Deslauriers et al., 2009). For this 
reason, if invasive nodal staging has not been performed preoperatively, it becomes 
mandatory to do so before proceeding with the sleeve resection (Faber, 1995; Yildizeli et 
al., 2007; Deslauriers et al., 2009). In case residual N2 disease is found at this stage, 
consideration for pneumonectomy or medical treatment instead of sleeve resection is 
prudent. 
 
h) Outcomes of sleeve resections 
Overall survival following sleeve lobectomy for patients with Non-Small Cell Lung 
Cancer (NSCLC) ranges from 39 %–53 % at 5 years and 28 %–34 % at 10 years (Tronc et al., 
2000; Fadel et al., 2002; Mezzetti et al., 2002; Kim et al., 2005; Ludwig et al., 2005; Ma et al., 
2007; Yildizeli et al., 2007; Deslauriers et al., 2009). 
In a series of 217 patients reported by Bagan et al in 2005, 5-year survival rates were 
recorded as high as 72 % (Table 1).  The report was limited to patients who underwent right 
upper lobe sleeve lobectomy, however, which has been suggested to be a less challenging 
operation when compared to other lobes (Bagan et al., 2005). Sleeve lobectomy for 
pulmonary carcinoid has excellent results with 5 and 10 year survivals ranging from 100 % to 
92 %, respectively (Fadel et al., 2002; Terzi et al., 2002). Documented factors decreasing long-
term survival following a sleeve lobectomy include incomplete resection and nodal 
involvement (Table 1) (Rea et al., 1997; Tronc et al., 2000; Fadel et al., 2002; Yildizeli et al., 
2007; Rea et al., 2008; Deslauriers et al., 2009). The influence on long-term survival of sleeve 
lobectomy from the squamous cell carcinoma type, age at resection, and induction 
radiotherapy remains unclear (Terzi et al., 2002; Yildizeli et al., 2007). 
Complications following sleeve lobectomy range between 15 % and 51 % of patients, 
as Predina et al described (Tables 1 and 2) (Predina et al., 2010). Common complications 
include sputum retention and secondary atelectasis.  Life-threatening complications include 
bronchovascular or bronchopleural fistula, and anastomotic failure (stricture and breakdown) 
(Tronc F, 2008). Bronchovascular fistula, bronchopleural fistula, and anastomotic failure can 
result from disruption of the bronchial blood flow during airway dissection or excessive 
tension at the anastomotic site. Bronchovascular fistula occurs in less than 2 % of cases of 
sleeve lobectomy but is one of the most feared complications (Tronc F, 2008). Bronchopleural 




fistula is slightly more common, occurring in 5 % of sleeve lobectomies (Tronc et al., 2000; 
Fadel et al., 2002; Mezzetti et al., 2002; Terzi et al., 2002; Yildizeli et al., 2007; Rea et al., 2008; 
Konstantinou et al., 2009). Death from bronchopleural fistula follows in approximately 40 % 
of the patients (Yildizeli et al., 2007; Rea et al., 2008). Anastomotic stricture or breakdown 
occurs in 1 %–4 % of patients undergoing sleeve lobectomy (Table 2 and 3) (Tronc et al., 2000; 
Fadel et al., 2002; Yildizeli et al., 2007; Rea et al., 2008). Post-operative or 30-day mortality 
for sleeve lobectomy is approximately 5 % in recent reports. Commonly documented causes 
of early mortality include bronchopleural fistula, bronchovascular fistula, cardiac 
complications, pneumonia or empyema, and pulmonary embolism. Less frequent causes 








5-Year Survival (%) 10-Year Survival (%) 
N0  N1  N2  N0 N1 N2  
Rea et al 
(1997) (Rea 
et al., 1997) 
179 72 36 22 59 27 14 
Icard et al 
(1999) (Icard 
et al., 1999) 
110 57 29 33 26 18 33 
Van Schil et 
al (2000) 
(Van Schil et 
al., 2000) 
145 62 29 31 53 21 6 
Table 1: Survival rates according to lymph node status after sleeve resection for NSCLC 
(Deslauriers et al., 2009). 
 
 






Patients 5-Year Survival (%) Complications (%) 30-Day Mortality (%) 
Konstantinou et al 
(2009) 
(Konstantinou et 
al., 2009) 45 57* 15 2 
Rea et al (2007) 
(Rea et al., 2008) 93 39.7 
Within 30 Days-17.9  
After 30 Days-16.3 
4.5 
 
Yildizeli et al (2007) 
(Yildizeli et al., 
2007) 218 53 22.9 4.1 
Mezzetti et al 
(2006) 
(Mezzetti et al., 
2002) 38 43 10.8 3.6 
Terzi et al (2002) 
(Terzi et al., 2002) 48** 38.8*** - 6** 
Fadel et al (2002) 
(Fadel et al., 
2002)**** 139 52 12.9 2.9 
Tronc et al (2000) 
(Tronc et al., 2000) 184 52 
Within 30 Days-14 % 
After 30 Days-2 % 1.6 
* Survival at 4 years 
** Results from “contemporary phase” which was described by authors as era after routine of CT, use of 
mediastinoscopy, and advanced bronchoscopic techniques 
*** Survival excludes stage IV patients 
**** Data includes both NSCLC patients and pulmonary carcinoid patients 
Table 2: 5-year survival, postoperative complications, and 30-day mortality results after 
sleeve lobectomy for NSCLC (Rea et al., 2008; Predina et al., 2010). 
 





* Includes only data of patients under 70 years age 
** Report is a meta-analysis 
*** Includes only data involving right upper lobe sleeve lobectomies and right pneumonectomies with limited 
nodal involvement (N0, intra-lobar N1 and skip metastasis) 
**** Complications only include those which took place during the early postoperative period 
 
Table 3: 5-year survival, 30-day mortality, and postoperative complications among NSCLC 























Melloul et al 
(2008)* (Melloul 
et al., 2008) 
115 - 0 26 - 3 44 
Ma et al (2007) 
(Ma et al., 2007) 
2984** 50.3 3.5 31.3 30.6 5.7 31.6 
Jiménez et al 
(2006) (Jiménez 
et al., 2006) 
255 56 2.8 36.1 32 9.1 36.3 
Bagan et al 
(2005) ***(Bagan 
et al., 2005) 
217 72.5 4.5 28.8 51.2 12.6 29.9 
Ludwig et al 
(2005) (Ludwig et 
al., 2005) 
310 39 4.3 38 27 4.9 26 
Kim et al (2005) 
(Kim et al., 2005) 
249 53.7 6.1 51**** 59.5 4.1 35**** 
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a) Eligibility for major anatomic resection 
There are multiple factors that have been related to eligibility for major anatomic 
resection and to perioperative risk.  Among them, patient characteristics (comorbidities, age), 
structural aspects related to the surgical center (volume, specialization), and process factors 
directly related with the management of complications and surgical access (open, minimally 
invasive) (Brunelli et al., 2013). Each of these play an important role.  These factors should be 
carefully considered when planning a pneumonectomy or sleeve resection. 
A meticulous cardiopulmonary evaluation is recommended in those patients who are 
sleeve resection candidates and it includes spirometry with predicted postoperative (ppo) 
FEV1 % values and diffusing capacity (DLCO %), a cardiac evaluation, and a cardiopulmonary 
exercise test when indicated. If any coronary stenosis is found, this should be treated prior to 
the lung resection (Figure 8) (Brunelli et al., 2010; Brunelli et al., 2013). 
 
Figure 8: Physiologic evaluation cardiac algorithm.*ThRCRI (Brunelli et al., 2010). 




In patients deemed high risk for lobectomy or greater operations, pneumonectomy 
should be avoided and thus, a sleeve resection, when possible, performed. This group of 
patients includes those with ppoFEV1 % and or ppoDLCO % < 30 %, high risk cardiac 
evaluation, cardiopulmonary exercise test with a VO2max < 10 ml/kg/min or <35 % (Figure 9) 
and those patients considered too frail to survive the operation (patients with significant 
weight loss, exhaustion, weakness, slow gate and in generally low activity) (Fried et al., 2001; 
Beckert et al., 2017). 
 
 
Figure 9: Physiologic evaluation resection algorithm (Brunelli et al., 2013). 
 
 




In those cases where pneumonectomy is the only suitable operation, it is important 
to remember that it has proven its oncologic value in fit surgical candidates, but it is 
associated with significantly decreased survival at 6 months (Rodríguez et al., 2013) and in 
early stage lung cancer patients (Jiménez et al., 2006; Rodríguez et al., 2015), mainly related 
to cardiopulmonary complications (Rodríguez et al., 2013) (Figure 10). 
 
 
                    Figure 10: Six-month death hazard of the pneumonectomy patients (matched 
cases) (Rodríguez et al., 2013). 
 
Although sleeve resections are technically described as a more challenging operation 
and were initially reserved for those patients with limited pulmonary function tests 
(Deslauriers et al., 2009), they have proven to offer similar short and long term results to 
those of pneumonectomy in the right candidates (Bagan et al., 2005; Kim et al., 2005; Ludwig 
et al., 2005; Ma et al., 2007; Melloul et al., 2008; Deslauriers et al., 2009). 
 




b) Landmark series 
The series reporting sleeve resections are not as common as those analyzing other 
types of procedures and the number of patients included is limited, too.  
The first significant series of bronchoplastic procedures was reported by Donald 
Paulson and Robert Shaw in 1959 (Paulson and Shaw, 1960) at the Southern Surgical 
Association meeting.  
In their article, they reported a series of 462 patients who underwent anatomic 
resection for bronchogenic carcinoma between January 1945 and December 1958.  Among 
those patients, 230 underwent a lobectomy (27 of them included a bronchoplastic procedure) 
and 232 patients underwent a pneumonectomy.  Of all patients undergoing surgery, 22 % 
survived 5 years.  This overall 5-year survival was further subdivided into 14 % of those having 
pneumonectomies and 30 % of those having lobectomies (Paulson and Shaw, 1960), (Table 4 
and Figure 11). 
 
Type of operation Number Deaths, n (%) 
Pneumonectomy 232 20 (8.6) 
Lobectomy 230 9 (3.9) 
Total 462 29 (6.2) 
 
Table 4: Operative mortality of Paulson and Shaw’s series (Paulson and Shaw, 1960). 





Figure 11: Survival curves of the series (Paulson and Shaw, 1960). 
 
In their series, 50 % of the patients undergoing a lobectomy survived at least two 
years, whereas only 25 % of the patients who underwent a pneumonectomy achieved that 
benchmark. The authors observed that, ‘bronchogenic carcinomas occur frequently in 
association with pulmonary emphysema and reduced pulmonary function, preservation of 
lung tissue where possible is of utmost importance’.  These authors advocated bronchoplastic 
operations to avoid pneumonectomy. 
In accordance with their philosophy of preserving as much parenchyma as possible, 
the authors performed bronchoplastic procedures for 3 main indications:  
1. As a curative procedure for low grade hilar lesions, preferably without 
nodal involvement, 
2. As a ‘compromise procedure’ for poor cardiac or pulmonary function, 
3. To ‘extend resectability’ of the extensive lesions involving the lower 
trachea, carina and contralateral main bronchus. 
In 8 years, from 1951 to 1959, they performed 27 bronchoplastic or sleeve procedures 
(2 tracheobronchial reconstructions and bronchoplastic procedures with lobectomy).  The 
first nine were reported separately (Paulson and Shaw, 1955). All the patients underwent 
surgery for bronchogenic carcinoma and all of the airway reconstructions were for hilar 
lesions. 




The 27 patients included in this initial series were men and their ages ranged from 47 
to 68 years. Two of the patients underwent the bronchoplastic procedure to extend 
resectability due to carinal and contralateral bronchus involvement. The remaining 25 
patients underwent the surgery as a curative procedure, 12 for small hilar lesions (eight 
without nodal involvement) and the other 13 patients were functionally compromised (nine 
with hilar involvement). The procedures performed are described in Figure 12. 
 
Figure 12: Types of bronchoplastic procedures done in 25 patients for bronchogenic 
carcinoma.  Panel 1 is right upper lobe resected with bronchoplasty, panel 2 is left upper 
lobectomy with bronchoplasty, panel 3 is right upper lobe sleeve resection, panel 4 is left 
upper lobe sleeve resection, panel 5 is right lower and middle lobes resected and right 
upper lobe preserved by sleeve, and panel 6 is left lower lobe sleeve resection (Paulson and 
Shaw, 1960). 
 
All of these bronchoplastic procedures were performed in combination with 
lobectomies. Wedge resection of the right main bronchus combined with a right upper 




lobectomy was performed once. Wedge resections of the left main bronchus combined with 
left upper lobectomy were done twice.  In three patients, the right middle and lower lobes 
and varying portions of the main bronchus were resected with anastomosis of the right upper 
lobe to the bronchial stump or trachea. 
Resection of the left lower lobe and a portion of the left mainstem bronchus with 
anastomosis of the left upper lobe to the main bronchus was done in 4 patients. Sleeve 
resection of the left main bronchus and pulmonary artery together, with a left upper 
lobectomy was done in one case. 
Based on their experience, the authors concluded that the greatest usefulness of 
sleeve resections was for lesions involving the right upper lobe bronchus, where a right upper 
lobectomy with anastomosis of the right main bronchus and the bronchus intermedius and a 
good nodal dissection achieved the same oncologic results as pneumonectomy but preserved 
the middle and lower lobes. They did this resection fourteen times in their series.  
The authors included a careful description of their technique, including placing the 
patients in prone position to facilitate anatomical exposure of the airway, and performance 
of the anastomosis with interrupted cotton sutures (Paulson and Shaw, 1960). They also 
explained the importance of the postoperative care, when the clearance of secretions 
becomes of utmost importance. They recommended naso-tracheal catheter aspiration 
systematically in all the patients and they placed up to four tracheostomies to prevent 
postoperative mucous plugging.  
Among the complications described in this series, the most common are 
bronchopleural fistula and empyema, with two patients dying in the first 30 days after the 
surgery and another two developing post anastomotic bronchial stenosis. Four of 27 patients 









Complications of sleeve resection n (%) 
Operative mortality 1 (3.7) 
Bronchial fistula 1 (3.7) 
Empyema 4 (14.8) 
Granulation tissue obstruction 3 (11.1) 
Obstructive bronchial stenosis 2 (7.4) 
Sutures removed bronchoscopically 5 (18.5) 
Recurrence carcinoma in the lumen 4 (14.8) 
 
Table 5: Complications in Paulson and Shaw’s series, including 27 sleeve resections (Paulson 
and Shaw, 1960). 
 
The patients who underwent a bronchoplastic procedure in this study had an 86 % 
survival at 2 years, 71 % survival at 3 years and 43 % survival at 5 years, which compared 
favorably to those who had undergone lobectomy (Figure 13). 
 
Figure 13: Survival curves of 22 patients having bronchoplastic procedures combined with 
lobectomies compared to 230 patients having lobectomies for bronchogenic carcinoma 
calculated by the life table method (Paulson and Shaw, 1960). 




Remarkably, all the patients who did not have nodal involvement were alive at 3 years 
and 70 % survived 5 years. With these results, the authors concluded that bronchoplastic 
procedures, when no nodal involvement can be observed, are an excellent alternative to 
more extended procedures and they should be widely used when technically feasible. 
From 1959, also, is the series of James Johnston and Peter Jones (Johnston and Jones, 
1959), who reported on 98 patients who had undergone any type of sleeve resection for 
bronchial carcinoma since 1953.  The patients were operated on in two hospitals: The Royal 
Brompton Hospital in London and the Baguley Hospital in Manchester. 
The ages of the patients included ranged from 30 to 79 years and among them were 
17 women. Similar to the series of Paulson and Shaw, most of their patients underwent a 
bronchoplastic or sleeve resection because their cardiorespiratory function did not allow a 
more extended resection. Also, two of the patients underwent the operation in the setting of 
isolated chest wall metastasis with palliative intent.   
The operations performed are shown in Table 6 (Johnston and Jones, 1959) and again, 
great emphasis is given to a careful bronchoscopic planning and chest cavity inspection to 
















Type of operation Number (%) 
Right upper lobe sleeve resection 47 (48) 
Right upper bilobectomy sleeve resection 12 (12.2) 
Right upper bilobectomy + apical lower sleeve resection 2 (2) 
Right lower bilobectomy sleeve resection 2 (2) 
Left upper lobectomy sleeve resection 30 (30.6) 
Left upper lobectomy + apical lower lobectomy sleeve resection 4 (4) 
Right upper lobectomy with sleeve resection of right and left main 
bronchus 
1 (1) 
 With chest wall 3 (3) 
 With sleeve pulmonary artery 5 (5.1) 
 With segmental pulmonary artery 3 (3) 
 
Table 6: Type of operation in 98 patients in Johnston and Jones (Johnston and Jones, 
1959). 
 
The authors’ techniques were very similar to that described by Paulson and Shaw and 
they advocated for apical and basilar chest tubes and daily or twice daily chest X-rays to 
facilitate the early detection and aggressive treatment of atelectasis. 
The main complications observed in this series were atelectasis, pneumothorax, atrial 










Early complications Number (%) 
Atelectasis requiring bronchoscopy 9 (9.18) 
Temporary pneumothorax 6 (6.12) 
Persistent air space 1 (1) 
Small infected pleural pocket 1 (1) 
Contralateral staphylococcal lung abscesses 1 (1) 
Pneumonia in anastomosed lobe 2 (2) 
Superficial wound infection 2 (2) 
Thrombophlebitis 2 (2) 
Pulmonary embolus 1 (1) 
Auricular fibrillation 9 (9.18) 
 
Table 7: Early complications in the series from Johnston and Jones (Johnston and 
Jones, 1959). 
 
Late complications Number (%) 
Sutures coughed up or removed 7 (7.14) 
Granulation tissue polyp at suture line 2 (6.12) 
Hemoptysis due to granulation tissue 1 (1) 
Temporary stenosis due to granulation tissue 1 (1) 
Other strictures early or late 0 (1) 
 
Table 8: Late complications in the series from Johnston and Jones (Johnston and 
Jones, 1959). 




In this series, the authors reported eight deaths directly related to the operation, 
accounting for 8 % of operative mortality. Among the eight deaths, two were attributed to 
coronary thrombosis, two to postoperative pneumonia and atelectasis, one secondary to a 
pulmonary artery thrombosis, one to bronchopleural fistula, one because of an intestinal 
obstruction, and the last patient died 6 weeks after the operation when receiving 
radiotherapy after a profuse episode of hemoptysis.  
Despite these deaths, the authors’ operative mortality rate of 8 % was comparable to 
the mortality rate observed after lobectomy at the Brompton Hospital during the same period 
in history.  Furthermore, the overall survival was better in the sleeve and bronchoplasty group 
than the one observed after lobectomies (Table 9). Consequently, they concluded sleeve 
resections were a safe operation to offer in the setting of bronchial carcinoma.  They also 
advocated for increased surgical indications, allowing those patients who were not good 
lobectomy candidates to undergo the sleeve operation with similar results to those achieved 
by lobectomies and better than those of the pneumonectomies (Table 10).  
 
Survival after 1 year compared with lobectomy Number  Alive, n (%) 
Sleeve resection 65 52 (80) 
Lobectomy (Price Thomas) 114 84 (74) 
 
Table 9: 1-year survival of sleeve resections compared to lobectomies (Johnston and 
Jones, 1959). 
Mortality rate according to age after pneumonectomy  Number  Dead, n (%) 
60 + 105 23 (22) 
50-59 163 33 (20) 
49 - 83 6 (7) 
 
Table 10: Mortality rate of pneumonectomy according to age (Johnston and Jones, 
1959). 




The conservation of lung tissue seemed to benefit both compromised and 
uncompromised patients, and with this background the next significant series of sleeve 
resections was published.  
It was in 1984 when Faber et al (Faber et al., 1984) presented their series of 101 
patients who underwent sleeve resection at Rush-Presbyterian-St. Luke’s Hospital in Chicago, 
and for the first time, patients who underwent preoperative irradiation were included in the 
study. 
The operations were performed between January 1962 and July 1982. The series 
consisted of 87 men and 14 women. The age ranged from 40 to 79 years. In the series 55 
patients had received preoperative irradiation (4000 rads given over 4 weeks). The radiation 
decision was made in the setting of a clinical trial for bronchial carcinoma treatment until 
1971 and electively afterwards. Most of the procedures performed were right upper lobe 
sleeve resections (Table 11).  All of them were considered curative and systematic nodal 


















Type of operation Number (%) 
Right bronchial sleeve resection 58 (57.4) 
 Right upper lobe sleeve resection 50 (49.5) 
 Right upper bilobectomy 2 (1.9) 
 Right upper bilobectomy + arterial sleeve resection 1 (0.9) 
 Right lower bilobectomy 1 (0.9) 
 Sleeve bronchus intermedius middle lobe 1 (0.9) 
 Sleeve bronchus intermedius lower lobe  1 (0.9) 
Left Bronchial sleeve resection 43 (42.57) 
 Left upper lobe sleeve resection 30 (29.7) 
 Left lower lobe sleeve resection 13 (12.8) 
 
Table 11: Sites of carcinoma in patients undergoing sleeve resection (Faber et al., 
1984). 
 
The authors also carefully described their techniques, especially the suture material 
used to perform the anastomosis. At the beginning of the series they used silk, but were 
dissatisfied with the high incidence of granulomas.  They switched to Tevdektm, yet that suture 
also produced granulation tissue at the anastomosis site. Finally, 3-0 coated polyglycolic 
suture (similar to Vicryltm) became the suture of choice.  They also emphasized the importance 
of cartilage to cartilage anastomosis, blood supply preservation by avoiding unnecessary 
bronchial dissection, and the placement of two or three sutures in the corners of the 
anastomosis to mitigate the tension in the remaining surfaces. They performed a systematic 
bronchoscopy in the operating room after finishing the anastomosis and if this was not found 
satisfactory, the airway anastomosis was redone immediately.  
Of the 101 patients, 7 patients underwent completion pneumonectomy for 
anastomotic problems and they were not included in further analysis. The remaining 94 




showed a 5-year survival of 30 % and a 10-year survival of 22 %. The sleeve lobectomy group 
that did not undergo irradiation (43 patients) had a 5-year survival of 34 % and a 10-year 
survival of 25 %. The 51 patients that had preoperative radiation had a 5-year survival of 25 
% and a 10-year survival of 16 % (Figure 14). These differences were not statistically significant 
(p= 0.102).  
 
Figure 14: Life-table analysis of 94 patients undergoing sleeve lobectomy for 














The TNM staging was not applied until 1972, but these authors analyzed their data 
accordingly.   The pathologic characteristics of the patients analyzed are shown in Table 12 
(Faber et al., 1984). 
 
Stage Radiation therapy 
 Yes, n (%) No, n (%) 
T1 N0 M0 7 (6.9) 16 (15.8) 
T1 N1 M0 3 (2.9)  7 (6.9) 
T2 N0 M0  16 (15.84) 10 (9.9) 
T2 N1 M0 9 (8.91) 12 (11.88) 
T3 N0 M0 2 (1.9)  1 (0.9) 
T1 N2 M0 1 (0.9) 1 (0.9) 
T2 N2 M0 4 (3.9) 3 (2.9) 
T3 N2 M0 1 (0.9) 1 (0.9) 
 
Table 12: Staging of sleeve lobectomies (Faber et al., 1984). 
 
Please note that in this early manifestation of the system of stage grouping, stage I 
included T1N1 (currently stage IIa).  Stage II only included T2N1 tumors (currently stage IIb).  
Finally, stage III included T3 tumors with direct invasion of the chest wall or mediastinum 
(possible to be stage IIa, currently) or with N2 disease (currently stage IIIa). 
Most of the patients with stage I who did not receive irradiation therapy had T2 N0 
M0 lesions. It is interesting to see that, among the patients treated with preoperative 
irradiation, almost half of them (16/33) had T1N0M0 lesions, probably secondary to the 
tumor downsizing produced by the irradiation. 
Patients with stage II lesions had positive hilar nodes and patients with stage III lesions 
had positive mediastinal lymph nodes. 




The 5-year survival rate of patients with stage I lesions was 36 % and the 10- year 
survival rate was 25 %. 5 year-survival for stage II patients was 18 % and 15 % for stage III 
(Figure 15). 
 
Figure 15: Life-table analysis of patients undergoing sleeve lobectomy for 
bronchogenic carcinoma by stage in Faber et al (Faber et al., 1984). 
 
The operative mortality of this series was 2 % (2 patients); one from inadequate 
ventilation during the procedure and the other secondary to adult respiratory distress 
syndrome. During the follow-up, 3 more deaths were observed; one due to myocardial 
infarction, one secondary to pneumonia and the last one after a fistula developed between 
the pulmonary artery and the bronchial anastomosis.  
Among the patients who required completion pneumonectomy for anastomotic 
dehiscence, 4 out of seven had received preoperative irradiation.  
There were 9 recurrences at the anastomotic site, most of them treated with radiation 
and chemotherapy.  
The authors, encouraged by their results despite the high recurrence rate observed in 
their series (10 %), recommended sleeve resection as the operation of choice when 




technically feasible and when the extent of the tumor permits it. They even recommended 
sleeve resection when the patient could tolerate a pneumonectomy (Faber et al., 1984). 
This report is of significant value not only because of the number of sleeve resections 
included, but also, because it is the first to include neoadjuvant treatment in the setting of 
sleeve resections. Although the indications for neoadjuvant irradiation in the series were 
based in a clinical trial and in surgeons’ preferences, the modern truth is that the current 
indications for neoadjuvant treatment in sleeve resection candidates remain unclear and 
controversial. 
The last remarkable report of sleeve resections is the one published by Hong et al in 
2018 (Hong et al., 2018).  Although the foci of their report were extended sleeve lobectomies 
(63 patients), they compared this extended group with their previous 20 years’ experience of 
477 sleeve lobectomies. The study included both patients with and without neoadjuvant 
chemoradiation therapy although the survival outcomes are not separately studied. Among 
the patients included in this report, 10.1 % in the sleeve lobectomy group received 
neoadjuvant chemoradiation. 
This paper focused on the influence of anastomotic complications on the outcomes 
of: length of stay, in-hospital mortality, recurrence rate, overall and disease-free survival, and 
postoperative complications. They also included in the analysis those patients who required 
a completion pneumonectomy for anastomotic problems (6 % in the extended sleeve 
resection group versus 2 % in the sleeve lobectomy group). This is the largest series of sleeve 
resections and bronchoplasties published to date.  The authors concluded that both sleeve 
resection and extended sleeve resection are feasible and safe operations for patients with 
centrally located NSCLC. 
 
c) Role of neoadjuvant therapy in sleeve resection candidates 
Most of the patients requiring sleeve resection are staged, by the 7th TNM 
classification (Goldstraw et al., 2007), as T2 (tumor involving the main bronchus but more 
than 2 cm away from the carina) or T3 (tumor < 2cm from carina or with involvement of the 
carina).   Regarding nodal stage, they are also frequently N1 (hilar nodes making airway 




dissection more challenging or affecting hilar structures) or N2 (Mediastinal lymph nodes 
affected, prompting neoadjuvant treatment and subsequent restaging). 
These classifiers make surgical candidates for sleeve resection at least stage IB (T2a 
N0 M0) according to both 7th and 8th edition (Detterbeck et al., 2017) of the TNM staging 
system.  Although, multimodality treatment is accepted worldwide as part of the 
management of locoregionally advanced NSCLC (at least stage IIIA), its benefits remain 
controversial in earlier stages of the disease. 
 
1.  Neoadjuvant chemotherapy in surgical candidates 
The role of neoadjuvant therapy in early stage lung cancer was initially studied with 
the hope of decreasing distant micro metastasis and local tumor burden, with the possibility 
of increasing resectability and improving overall survival. 
In the early 1990s, two randomized trials of neoadjuvant chemotherapy in patients 
with resectable NSCLC demonstrated increased survival when adding preoperative platinum 
based chemotherapy to surgery than with surgery alone (Roth et al., 1994; Rosell et al., 1999).  
Critics of these studies pointed out the small number of patients included, the unexpected 
poor outcomes in the control arm and the great heterogeneity of the populations studied.  
In 2006, seven neoadjuvant therapy randomized trials were included in a meta-
analysis. It consisted of 988 patients and was able to demonstrate an overall survival 
improvement of 20 % in the treatment group compared with only 14 % (p= 0.02) in the control 
group (Burdett et al., 2006). Among the studies included in this meta-analysis, three of the 
largest ones were primarily responsible for the differences observed.   
Among them, the study from Depierre et al (Depierre et al., 2002) randomized 355 
patients staged from IB to IIIA to two cycles of neoadjuvant cisplatin, ifosfamide and 
mitomycin followed by surgery versus surgery alone.  Those patients who had a good 
preoperative response (64 %) received two additional adjuvant cycles after surgery. Patients 
diagnosed with pT3 or N2 disease received neoadjuvant radiation (40 Gy delivered in 2 Gy 
daily fractions 5 days per week). It is important to remember that in this study, mediastinal 
staging and lymph node dissection or sampling were left to the discretion of the surgeon and 
no lesser operation was allowed even if the disease had shrunk enough to consider it. In total, 




355 patients were randomized. Response to preoperative chemotherapy was 64 %, with two 
deaths related to the neoadjuvant treatment. Postoperative mortality was 6.7 % in the 
neoadjuvant group and 4.5 % in the surgical group (p= 0.38). Median survival was 37 months 
in the preoperative chemotherapy group and 26 months in the surgical group (p=0.15). 
Overall survival of the patients included in the neoadjuvant therapy group increased from 3.8 
% the first year to 8.6 % at 4 years with significant benefit observed among N0 and N1 patients 
(p=0.027).  After a non-significant excess of deaths during the treatment period, the effect of 
neoadjuvant chemotherapy was deemed beneficial on survival (p= 0.044). In addition, disease 
free survival was significantly increased among those patients who received neoadjuvant 
chemotherapy (p= 0.033). As the authors did not find increased deaths or morbidity in the 
neoadjuvant group compared with the control group (6.7 % deaths versus 4.5 % deaths, 
p=0.38) they concluded neoadjuvant therapy was a safe practice for those patients with 
resectable lung cancer. 
On counter balance, a multicenter randomized controlled trial designed by Gilligan et 
al (Gilligan et al., 2007) failed to show any differences between cisplatin-based chemotherapy 
versus surgery alone. The study included 588 patients from 4 different centers diagnosed with 
stage I to stage III NSCLC. The overall survival observed in the experimental group was 44 % 
versus 45 % in the control group (Hazard Ratio: 1.02). Interestingly, up to 33 % of the patients 
included in the chemotherapy arm were downstaged, but this did not affect the planned 
surgery. No increased surgical mortality and morbidity were observed in the chemotherapy 
group. The main limitations of this study, (limitations that could have contributed to its 
negative results) were the different chemotherapy regimens (up to 6 different regimens were 
allowed) and the large number of stage I patients included (61 %), making it more difficult to 
reach statistical significance. 
In 2007, the results of the Southwest Oncology Group (SWOG) 9900 trial were updated 
and presented.  388 patients diagnosed with resectable lung cancer were randomized to 
surgery alone versus three cycles of neoadjuvant carboplatin and paclitaxel. Although it was 
not statistically significant, a trend towards increased 5-year overall survival was observed in 
the experimental arm (43 % versus 50 %, Hazard Ratio = 0.81) (Pisters et al., 2007). 
Several other Phase II studies including cisplatin/vindesine/ifosfamide (Lorent et al., 
2004), cisplatin/vinblastine (Sugarbaker et al., 1995), cisplatin/docetaxel (Betticher et al., 




2003) and cisplatin/gemcitabine (Migliorino et al., 2002) combinations have been able to 
demonstrate the role of other new generation agents as neoadjuvant treatment. 
All these studies present several limitations as to the inability to properly stage 
patients preoperatively (Staging was mostly radiologic, with few insisting on pre-resectional 
pathologic staging such as CALGB study 8935 (Sugarbaker et al., 1995)), the great variability 
of the chemotherapy regimens and the different stages of lung cancer included in each 
randomized trial. Even with the limitations stated above and the subsequent difficulties 
interpreting the data, all of them suggested a role for induction chemotherapy for patients 
with stage II or IIIA NSCLC who were operable candidates. 
 
2.  Postoperative complication risk after neoadjuvant chemotherapy 
There have been controversial reports regarding the risk of postoperative 
complications in those patients who have undergone neoadjuvant therapy.  
In 2001 Roberts compared 34 patients who underwent neoadjuvant chemotherapy 
with 67 that did not. The patients were matched by age, comorbidity and pulmonary function.  
In the group of patients that received neoadjuvant chemotherapy, an increased rate of life 
threatening complications such as postoperative pneumonia, emergency surgery, ICU 
admission or reintubation was found (6.0 % versus 26.5 %, P = .0036). Major complications, 
including prolonged hospital stay (19.4 % versus 47.1 %, P = .0037), reintubation (3.0 % versus 
17.6 %, P = .0093), and tracheostomy (0 % versus 11.8 %, P = .0042) were also higher among 
the patients treated with induction chemotherapy (Roberts et al., 2001). 
Although this study was criticized because there was no matching by stage between 
the two groups, and patients in the chemotherapy group had a higher stage, it was the first 
study that raised the concern of postoperative complications after induction chemotherapy.  
In another retrospective study of 106 patients, Venuta et al demonstrated 
neoadjuvant chemotherapy did not increase complications in experienced surgeon’s hands 
(Venuta et al., 2007). 
Among the results of several studies trying to assess the risk of complications after 
neoadjuvant chemotherapy, it is important to discuss the results found by Mansour et al. They 




analyzed 306 patients who underwent pneumonectomy from January 1999 to July 2005 after 
neoadjuvant chemotherapy and they found no increased postoperative mortality (Mansour 
et al., 2007). However, Martin et al, reviewing Memorial Sloan Kettering Cancer Center 
database, from 1993 to 1999 found an increased mortality (23.9 %) in patients who 
underwent a right pneumonectomy after induction chemotherapy (Martin et al., 2001). 
With this information, it became a classical recommendation to avoid right 
pneumonectomy after neoadjuvant chemotherapy.  
 
3.  Neoadjuvant versus adjuvant chemotherapy 
Another question that remains unanswered is the best timeline for chemotherapy 
administration in relationship with surgery.  Specifically, should chemotherapy be given prior 
to surgery (neoadjuvant) or after recovery from surgery (adjuvant). 
Many authors have tried to address this issue with randomized controlled trials.  
Among them, the Neoadjuvant/Adjuvant Taxol (paclitaxel) Carboplatin Hope (NATCH) 
trial from the Spanish Lung Cancer group, included patients with stage I (> 2 cm), II, and T3, 
N1 NSCLC. The study candidates were randomized to neoadjuvant or adjuvant 
carboplatin/paclitaxel or surgery alone. The preliminary results from the neoadjuvant arm 
demonstrated neoadjuvant chemotherapy could be a safe alternative to those patients with 
resectable NSCLC (Felip et al., 2007). 
The final results of this trial were reported in 2009, at the World Congress on Lung 
Cancer (Felip et al., 2010).The study included a total of 624 patients and among them there 
was no significantly different progression-free or overall survival observed. In the groups of 
induction chemotherapy, adjuvant chemotherapy, and surgery alone, the 5-year progression-
free survival rates were 38.3 %, 36.6 %, and 34 %, and the 5-year overall survival rates were 
46.6 %, 45.5 %, and 44 %, respectively. There were multiple limitations in the study, including 
the fact that most of the patients included were staged as IA and IB. Also, a lot of patients 
included in the adjuvant chemotherapy group were not able to receive the originally planned 
three cycles of treatment due to postoperative morbidity.  The implication of this trial is that 
adjuvant therapy may be comparable to neoadjuvant therapy for stage I and II non-small cell 




lung cancer.  That would have implications for timing of sleeve and bronchoplastic 
procedures. 
The Chinese Society of Lung Cancer also designed the Survival Study of Docetaxel and 
Carboplatin as Neoadjuvant vs Adjuvant Chemotherapy in Early-Stage NSCLC (NCT00321334) 
with similar controversial results (Yang et al., 2013). 
The International Adjuvant Lung Cancer Trial Collaborative Group randomized a total 
of 1867 patients diagnosed with NSCLC who underwent complete resection of their 
malignancies.  36.5 % were diagnosed with pathological stage I disease, 24.2 % with stage II, 
and 39.3 % with stage III disease. 932 patients underwent cisplatin based adjuvant 
chemotherapy, with etoposide in 56.5 % of patients, vinorelbine in 26.8 %, vinblastine in 11.0 
%, and vindesine in 5.8 %. The median duration of follow-up was 56 months. Patients assigned 
to chemotherapy had a significantly higher survival rate than those assigned to observation 
(44.5 % versus 40.4 % at 5 years [469 deaths versus 504] P<0.03). Patients assigned to the 
chemotherapy arm also had a significantly higher disease-free survival rate than those 
assigned to observation alone (39.4 % vs. 34.3 % at 5 years [518 events versus 577]; P<0.003). 
There were seven deaths related to chemotherapy toxicity (0.8 %) and there was no 
neoadjuvant therapy arm, but the conclusions favored significantly the administration of 
cisplatin-based chemotherapy after completely resected NSCLC (International Adjuvant Lung 
Cancer Trial Collaborative, 2004). 
Another systematic review of 31 randomized trials, including 21 with postoperative 
chemotherapy and 10 with induction chemotherapy, with more than 10000 patients 
analyzed, was not able to find any differences in patients’ mortality and morbidity, disease-
free survival and overall survival between both groups, suggesting the timing of 
chemotherapy, after of before the surgery has very little impact in postoperative results (Lim 









4.  Role of radiation therapy in NSCLC 
Radiation therapy has an important and well-established role in the management of 
NSCLC. Although, most of the times it is recommended with concurrent chemotherapy, it can 
be administered alone (Mohiuddin and Choi, 2005). 
Radiation treatment is currently well accepted for six major indications: medically 
inoperable stage I and II NSCLC, postoperative radiation therapy for stage II and III, 
neoadjuvant treatment with chemotherapy for marginally resectable stage III disease, 
definite treatment for bulky stage II and stage III disease, neoadjuvant treatment for superior 
sulcus tumors and palliation (Mohiuddin and Choi, 2005). 
For this topic, we will just focus in marginally resectable stage III disease where 
radiation therapy is administered with concurrent chemotherapy to try to downstage those 
patients who would be good candidates for a surgical resection, trying to provide, with both 
together, a better overall survival (Albain et al., 1995). 
A lot of improvements have been achieved since the 1980’s where, according to 
several surgical series, only few patients could undergo a complete surgical resection after 
neoadjuvant treatment (Mohiuddin and Choi, 2005). Martini et al (Martini et al., 1980) 
reported in 1980 a series of 445 patients who underwent neoadjuvant chemotherapy and 
radiation for marginally resectable stage III disease. All the patients were clinically and 
pathologically staged and among them, 241 underwent surgical exploration. Of these, 80 
patients had complete surgical resections, leading to a 3-year survival among this select group 
of 49 %, compared with the overall survival rate of 13 % among all patients with N2 disease.  
Among those patients who did not receive neoadjuvant treatment, only 7 % were able to 
undergo a complete resection.  
Following the lead of these results, the phase II trial from the Cancer and Leukemia 
Group B (CALGB) 8935 showed that those patients who were included in the multimodality 
treatment arm (neoadjuvant chemotherapy and adjuvant sequential chemotherapy followed 
by radiation therapy) achieved better survival than with historical benchmarks of surgery 
alone (17 % versus 13 % 5- year overall survival).  This study included mediastinoscopy-staged 
N2 patients who received two cycles of chemotherapy followed by thoracotomy followed by 




2 additional cycles of chemotherapy and 54.0 to 59.4 Gy of postoperative radiation therapy 
(Sugarbaker et al., 1995). 
The next important trial was the small phase II study designed by Fleck et al (Fleck et 
al.) In this trial, authors compared the addition of radiation to chemotherapy as neoadjuvant 
treatment versus chemotherapy alone.  In the study, two cycles of cisplatin and continuous 
infusion 5 FU with 30 Gy of radiation in 15 fractions resulted in a higher response rate (67 % 
versus 44 %), resection rate (52 % versus 31 %), and 3-year progression free survival (40 % 
versus 21 %) than chemotherapy alone.  
It was clear after these studies that the main benefit from concurrent chemoradiation 
therapy was downstaging.  
Another study from the Massachusetts General Hospital showed this advantage in 
detail. 42 patients with mediastinoscopy proven N2 disease underwent neoadjuvant 
treatment with cisplatin, vinblastine, and 5 FU along with 21 Gy at 1.5 Gy bid with a 10-day 
break for esophagitis recovery followed by another 21 Gy bid. After surgery, additional 
radiation was administered (12 to 18 Gy, with a total dose of 54 to 60 Gy) and one more cycle 
of chemotherapy was added. Almost 89 % of the patients had a complete resection of their 
tumors and two thirds of the patients diagnosed with stage IIIA (N2) disease were downstaged 
to N0 and N1. Downstaging was related again with an improvement of 5-years overall survival 
from 18 % to 42 % (Choi et al., 1997). 
The Southwestern Oncology Group (SWOG) 8805 trial was a phase II study designed 
to analyze the effects of concurrent neoadjuvant chemoradiation therapy followed by surgery 
in locally advanced NSCLC (Albain et al., 1995).  126 patients were included in the study. 
Among them, 75 were diagnosed with stage IIIA (with N2 involvement) and 51 were staged 
as IIIB disease. Patients received two cycles of chemotherapy with cisplatin and etoposide and 
concurrent radiation therapy with 45 Gy. Patients with good response to the treatment or at 
least stable disease underwent surgical resection, whereas those with disease progression 
continued to receive further chemoradiation.  The overall 3-year survival rate was 26 % with 
the trimodality treatment. Among those patients who underwent surgery, the 3-years survival 
rate was 44 % when the nodal disease had been eradicated by the neoadjuvant treatment 
and 18 % in those patients with persistent mediastinal disease. 




This study was designed based on a previous study by Friess et al (Friess et al., 1987) 
from 1987 that included patients with advanced NSCLC. Patients underwent four 1-month 
cycles of cisplatin and etoposide along with radiation therapy up to 60 Gy. The median survival 
achieved in the study was 16 months, with a 30 % 2-year survival rate.  
In the Intergroup 0139 (Albain et al., 2009) trial, 396 patients were included. They 
were diagnosed with stage IIIA (pathological N2) NSCLC. Patients were randomized to two 
arms, one receiving induction cisplatin/etoposide with concurrent 45 Gy of radiation followed 
by surgery and two more cycles of chemotherapy afterwards and the other arm receiving 
cisplatin/etoposide with 61 Gy of radiation followed by two more cycles of chemotherapy. 
The progression free survival was higher in the trimodality treatment arm (12.8 
months versus 10.5 months, p= 0.017). On the other hand, in the trimodality treatment there 
was only minimal benefit in the 5-years survival rate (27.2 % versus 20.3 %). Similar to the 
results of the SWOG 8805 study, the downstaging to pN0 at the time of the surgery predicted 
the long-term survival.  Five-year survival was 41% in patients with pN0 at the time of surgery 
and 24 % in patients with residual mediastinal disease.  
One of the most important findings of the Intergroup 0139 study was the increased 
mortality when performing a pneumonectomy after induction chemoradiation therapy. 7.9 % 
of patients in the trimodality group had a treatment related death versus 2.1 % of the patients 
in the chemotherapy alone group. Almost 5 % of the deaths in the trimodality arm occurred 
within 30 days from the surgery and 9 out of 10 deaths were in patients who had undergone 
a pneumonectomy. 
These findings were correlated with an increased risk of mortality of pneumonectomy 
after induction chemoradiation and led to a stratified analysis. Those patients in the study 
who had undergone a lobectomy did better when compared to those who needed a 
pneumonectomy. The 5-years survival of those patients who had undergone a lobectomy was 
36 % and decreased to 22 % in pneumonectomy patients. 
Other investigators also reported increased mortality among pneumonectomy 
patients when neoadjuvant chemoradiation was administered (Deutsch et al., 1994; Martin 
et al., 2001). 




Gaissert at al (Gaissert et al., 2009) further investigated the role of pneumonectomy 
after neoadjuvant chemoradiation therapy. In their retrospective study, they included 183 
patients who underwent pneumonectomy, 46 of them after concurrent chemoradiation. The 
46 patients who received neoadjuvant treatment had disease ranging from IIB to IV, but they 
were also younger and with better cardiac and pulmonary function. Hospital mortality was 
4.3 % after neoadjuvant therapy and 6.6 % after resection only. Although they concluded 
pneumonectomy after neoadjuvant chemoradiation therapy is a safe option in carefully 
selected patients, they also recommended avoiding it when possible, in favor of lung 
parenchyma sparing operations. 
Overall, preoperative concurrent chemoradiation seems a valid option to help 
downstage patients with NSCLC, facilitating in most of the cases the performance of a 
complete resection or of a parenchyma sparing operation. However, the inflammatory, 
immune and systemic responses to radiation therapy and the impact they could have in the 
healing of the anastomosis after sleeve resection are not yet well understood.  
In their study from 2000, Yamamoto et al (Yamamoto et al., 2000) investigated the 
role of neoadjuvant radiation in bronchial mucosal blood supply and consequently in healing. 
They included 90 patients and divided them in 3 groups: patients who did not have any 
neoadjuvant treatment, patients who had chemotherapy alone and patients who had 
chemoradiation (60 Gy). They measured the bronchial mucosal blood flow preoperatively, 
intraoperatively, and postoperatively (days 8-10) with a laser Doppler flowmeter. 
They observed that bronchial mucosal flow was preserved among patients who did 
not receive any neoadjuvant treatment and among those who received chemotherapy alone, 
regardless of the extent of the lymphadenectomy.  However, the blood flow was 
compromised in those patients who underwent neoadjuvant radiation and it decreased still 
farther after the lung resection. Although they only observed one bronchopleural fistula 
among their patients, they recommended routine coverage of the bronchial stump with a 
pedicled flap in those patients who had undergone radiation therapy. 
Different studies have shown the effects of the surgical anastomosis and radiation on 
the bronchial vasculature, ranging from congestion and edema in the acute period (within 4 
weeks from radiation) to hyalinization of arterioles and fibrosis in the subacute and late 




periods (Yokomise et al., 1989; Inui et al., 1993; Sundset et al., 1993; Korpela et al., 1995; 
Muehrcke et al., 1995; Hyytinen and Halme, 2000). 
Although the bronchial microcirculation has two blood sources, the bronchial arteries 
and the pulmonary circulation (Kröll et al., 1987), it is difficult to predict in which patients an 
increase in pulmonary blood flow would be able to compensate for the decrease in bronchial 
circulation (Sundset et al., 1993). 
Another factor that seems to be related with the incidence of bronchial complications 
after neoadjuvant chemoradiation is the radiation dose, especially when it exceeds 35 or 40 
Gy (Tsubota et al., 1975; Warram, 1975; Mathisen et al., 1988). Inui and colleagues 
experimental findings support this theory (Inui et al., 1993), leading to the conclusion that the 
safer radiation dose would be 36 Gy or less. According to their data, the healing of the 
bronchial anastomosis was directly related to the bronchial mucosal blood flow. When the 
radiation dose increased over 36 Gy, the blood flow decreased at least 60 % compared to the 
preoperative level, leading to an increased rate of bronchial complications. Other authors 
have recommended laser Doppler flow to try to predict the incidence of bronchial 
complications, and although it has been used to assess microvascular perfusion in other 
organs, its clinical implications in sleeve reconstructions remain unclear (Ahn et al., 1985; 
Kvernebo et al., 1986; Yokomise et al., 1989; Sundset et al., 1993; Korpela et al., 1995; 
Hyytinen and Halme, 2000). 
To summarize, neoadjuvant chemotherapy has shown to be an acceptable option for 
those patients that have a good response to it and can tolerate a surgical resection.  Careful 
consideration of avoiding neoadjuvant radiation therapy should be given to those cases 
requiring a pneumonectomy or a bronchial anastomosis because of the side effects that 
radiation therapy can have in bronchial circulation and consequently in bronchial healing.  
 
d) Quality of life after pneumonectomy and sleeve resection 
There are very few studies analyzing quality of life after pneumonectomy and sleeve 
resection, none of them randomized and just some of them compare quality of life between 
both types of surgeries. 




It seems accepted that quality of life in patients undergoing lung resection for NSCLC 
tend to deteriorate with the extent of the resection, especially with pneumonectomy 
(Hamberger and Pichlmaier, 1996; Möller and Sartipy, 2012; Pompili, 2015).  Zieren et al in 
their study in 1996, found more shortness of breath on exertion among those patients who 
had undergone a pneumonectomy compared to those who had a lobectomy. When 
compared to the preoperative assessment, quality of life deteriorated significantly at 
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Table 13: Differences in the main quality of life scores between pneumonectomy and 
lobectomy (Pompili, 2015). (EORTC: European Organization for Research and Treatment of 
Cancer; PF: Physical function; SF: Social function; RF: Role function; GH: General Health; CF: 
Cognitive function; PCS: Physical composite score, Shoulder dysf: Shoulder dysfunction) 
 
Although it is tempting to assume that the QoL outcomes of sleeve lobectomy are 
comparable to those of lobectomies, this remains unclear and data concerning sleeve 
lobectomy are minimal. Ferguson et al in 2003, compared sleeve lobectomy and 
pneumonectomy in a meta-analysis. They included 99 studies and afterwards calculated 
postoperative quality-adjusted life years (QALY) using a statistical decision model. With their 




analysis, they concluded that sleeve lobectomy provided a favorable overall QoL and QALY 
advantage when compared to pneumonectomy (Ferguson and Lehman, 2003). 
Schulte et al found worse reported postoperative quality of life among those patients 
who had undergone a pneumonectomy, with significantly worse postoperative values 
(statistical difference in physical function at 3 months, social function at 3-6 months, role 
function at 3-6-12 months, general health at 3-6 months and pain at 6 months) compared to 
those who had had a lobectomy or a bilobectomy (Table 13) (Schulte et al., 2009). 
Balduyck et al in 2007, confirmed this finding. They studied 100 pneumonectomy 
patients and found that they were not able to recover their baseline values in physical 
function, role function, pain, shoulder dysfunction and dyspnea scales in a 12-month period 
(Balduyck et al., 2007). A year later, the same group published one of the rare prospective 
quality of life studies comparing pneumonectomy with sleeve resection (Balduyck et al., 
2008). In this study, sleeve lobectomy patients recorded a one-month temporary decrease in 
physical function and social function after surgery.  Global quality of life, symptom, and pain 
related scores returned to preoperative values approximately one month after sleeve 
lobectomy. On the other hand, pneumonectomy patients were not able to return to their 
baseline in physical and role function in a 12-month follow up period.  
Leo et al also confirmed the negative impact of pneumonectomy in quality of life, with 
25 % of patients after pneumonectomy experiencing impaired quality of life after the surgical 
resection (Leo et al., 2010). 
Sartipy also was able to identify the extent of the parenchymal resection as the 
strongest predictor of physical quality of life decline 6 months after the operation (Sartipy, 
2009). However, the mental components did not differ between patients undergoing a 
lobectomy or a pneumonectomy.  
Brunelli et al also reported similar results, finding significantly lower physical 
composite score among patients with pneumonectomy, but similar mental composite score 
3 months after the operation (Brunelli et al., 2007). 
Although there is still much room for improvement in measuring quality of life after 
lung resection and there are rare studies comparing sleeve resection and pneumonectomy, 
based on the current evidence, it seems clear pneumonectomy has the worst effects in quality 




of life among all the anatomical lung resections, making appropriate, when possible, to 


















































The hypothesis of this study is:  
Neoadjuvant chemoradiation therapy may be associated with an increased risk of 
postoperative pulmonary and airway complications after sleeve resection of the lung and 
these complications may have a negative impact on the overall survival of this group of 






















































a) Main objectives: 
1. Analyze the association between the incidence of postoperative pulmonary 
complications and airway complications in patients undergoing pulmonary 
sleeve resection with or without the use of neoadjuvant chemoradiation 
therapy. 
 
2. Analyze the overall survival of the patients who underwent sleeve resection 
with and without neoadjuvant chemoradiation therapy and specifically in 
those patients who were diagnosed with NSCLC. 
 
b) Secondary objectives: 
1. Analyze the characteristics of the population of patients submitted to 
sleeve resection of the lung. 
2. Analyze the distribution of the risk-related variables in the studied 
population. 
3. Analyze the incidence of postoperative pulmonary complications among 
patients who underwent a sleeve resection of the lung in the whole series 
and by type of resection. 
4. Analyze the incidence of airway complications among patients who 














































MATERIALS AND METHODS: 
 
a) Choice of Data Set 
The operative experience of the Brigham and Women’s Division of Thoracic Surgery in 
Boston was chosen as the data set to test these hypotheses.  This data set provided a very 
large clinical volume with a standardized approach to patient care. 
 
b) Studied population 
We have reviewed a prospective cohort of 143 patients who underwent sleeve 
resection for any indication in our Institution between January 1998 and December 2016.  The 
considered exposure was the administration of neoadjuvant chemoradiation prior to the 
sleeve resection. All the information was retrieved from a prospectively recorded database 
with double quality audit of the data introduced.  
 













Figure 16: Inclusion criteria flow diagram 
 
Sleeve and Bronchoplastic resections  
(n = 164) 
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c) Perioperative management 
Before the operation, patients’ work up included physical examination, hematological 
and biochemical tests, electrocardiogram, chest X-rays, CT scan of the chest, PET-CT, 
bronchoscopy and EBUS or cervical mediastinoscopy when needed. Other tests were only 
indicated if previously obtained results suggested them.  
Pulmonary function tests were routinely indicated in all patients. In this study, we 
have analyzed FEV1 % and DLCO % values according to age, gender and height of the patient. 
All patients with previous history of relevant cardiovascular disease were referred to 
the cardiologist for further assessment and a stress test was routinely ordered. As a common 
practice, coronary stenoses were stented or by-passed before lung surgery. 
Perioperative management was uniform for all the patients along the study period. All 
cases were anesthetized and operated on under the supervision of the same team of senior 
cardio-thoracic anesthetists and thoracic surgeons, respectively. Prophylactic antibiotic 
regimen was based on a standard dose of Cefazolin 2000 mg that was repeated 6 hours later 
if surgery continued.  
The surgical technique has been described elsewhere (Mentzer et al., 1993; Mentzer, 
1998; Konstantinou et al., 2009) but briefly, it consisted in a preoperative flexible 
bronchoscopy to assess endobronchial tumor extension and plan the needed resection.  It 
includes circumferential dissection of the bronchus or the pulmonary artery or both, with the 
best possible oncologic margins and paying attention, in the case of the bronchus, to preserve 
an appropriate blood supply. The bronchial anastomosis was performed using either a 
continuous running monofilament suture or interrupted VicrylTM suture.  In general, the 
posterior aspect of the anastomosis is performed first along the mediastinal face of the 
bronchus starting at the cartilaginous–membranous juncture.  Sewing is continued to the 
middle of the cartilaginous ring. Circular pulmonary artery anastomosis was performed when 
needed, using 5/0 polypropylene suture. All the anastomoses were systematically covered by 
intercostal muscle flaps harvested during the thoracotomy, pleural flaps or pericardial fat pad 
flaps depending on the surgeon’s preferences. Before extubation, a routine bronchoscopy 
was performed to check the anastomosis and to clean up remaining secretions. 
All the patients were extubated in the operating room and, after approximately 6 
hours in the recovery room, they were transferred to the TICU. Postoperative analgesia 
consisted of an epidural catheter with bupivacaine and fentanyl infusion during the first 3 




days or until the chest tube was removed, oral oxycodone or dilaudid, and non-steroid anti-
inflammatory drugs and narcotics, when needed, thereafter. Nursing care was homogeneous 
in all cases and included chest physiotherapy and early mobilization of the patients. 
 
d) Variables and outcomes 
The outcomes selected as dependent variables were the occurrence of postoperative 
pulmonary complications and the occurrence of airway complications.  
Among the postoperative pulmonary complications, any of the following 
postoperative events were considered: pulmonary atelectasis requiring bronchoscopy, 
pneumonia or both. Positive diagnosis was provided if any of the postoperative chest 
radiographs reported consolidation or atelectasis, when leukocytosis (WBC over 11000 x 
106/L) and fever (Body temperature >38ºC) of pulmonary origin according to the attending 
surgeon, when a positive sputum culture was present or there was a change in the quality of 
the sputum respect to the preoperative sputum and, finally, if respiratory insufficiency 
(Sp02<90 % on room air) is present measured by a peripheral pulsioximetry (American 
Thoracic Society and Infectious Diseases Society Of America, 2005). 
Among the airway complications, stenosis requiring dilation, bronchopleural fistula, 
bronchovascular fistula and need for completion pneumonectomy for anastomosis 
breakdown were considered. 
Definitions for each type of postoperative complication were agreed in advance by all 
team members and all adverse events were recorded at patient’s discharge on real time.  
Completeness and accuracy of all records were audited by a data manager at the time 
of patient’s discharge. 
The independent variables included in the analysis were: Age, BMI, FEV1 %, FVC %, 
DLCO %, the presence of coronary artery disease, NSCLC diagnosis and the neoadjuvant 
treatment status.  
Although we planned to include renal insufficiency as an independent variable in the 









e) Statistical considerations 
The dataset includes 143 independent patients who were submitted to a surgical 
procedure, in this case sleeve resection, at the Brigham and Women´s Hospital between 
January 1998 and December 2016.  
The studied intervention was the administration or not of neoadjuvant 
chemoradiation treatment and the outcomes of interest were the incidence of postoperative 
cardiopulmonary complications and airway complications and the overall survival. 
To analyze the outcomes, logistic regression methodology was selected, including as 
covariates general demographic features of the patients (age, gender, date of surgery, weight, 
height, FEV1 %, FVC %, DLCO %, Coronary artery disease) and clinical variables as diagnosis of 
NSCLC, clinical and pathological stage and type of surgery. 
The complications studied were defined in advance and submitted to a double quality 
audit when coding them on the database. Furthermore, they were coded individually as 
pneumonia, atelectasis, stenosis, bronchopleural fistula, bronchovascular fistula and need for 
completion pneumonectomy and they were grouped in postoperative pulmonary 
complications and airway complications for analysis purposes.  
The distribution of the continuous numerical variables in the population was studied 
with the Skewness/Kurtosis test.  
Multicollinearity was also tested using the tolerance (an indicator of how much 
collinearity a regression analysis can tolerate) and VIF (variance inflation factor, an indicator 
of how much of the inflation of the standard error could be caused by collinearity) (Mansfield 
and Helms, 1982). 
Once multicollinearity was dismissed, all the selected variables were kept in the 
model. Each model´s fit was tested with the Hosmer and Lemeshow’s goodness-of-fit test 
(Hosmer Jr et al., 2013). 
 
1. Estimation and comparison of postoperative pulmonary complication rates 
The incidence of postoperative pulmonary complications was determined for the 
whole series and for both groups: the patients who had received neoadjuvant treatment and 
those who had not. Finally, a logistic regression model was created, including the incidence 
of postoperative pulmonary complications as dependent variable and Age, BMI, FEV1 %, FVC 




%, DLCO %, the presence of coronary artery disease, NSCLC diagnosis and the neoadjuvant 
treatment status as independent variables. 
 
2. Estimation and comparison of airway complication rates 
The incidence of airway complications was determined for the whole series and for 
both groups: the patients who had received neoadjuvant treatment and those who had not. 
Finally, a logistic regression model was created, including the incidence of airway 
complications as dependent variable and Age, BMI, FEV1 %, FVC %, DLCO %, the presence of 
coronary artery disease, NSCLC diagnosis and the neoadjuvant treatment status as 
independent variables. 
 
3. Estimation and comparison of overall survival rates 
The overall survival was determined for both groups and for the subset of patients 
that were diagnosed with NSCLC. Kaplan Meier overall survival curves were designed for this 
purpose for both, the whole series, and the patients diagnosed with NSCLC. The curves were 
tested with log rank test. 














































Between January 1998 and December 2016, 143 patients underwent sleeve resection 
at the Brigham and Women’s Hospital in Boston. 
The characteristics of the variables studied in the population are as follows: 




Figure 17: Distribution of variable Age in the studied population. 
 





















Figure 18: Distribution of variable BMI in the studied population. 
 



















Figure 20: Distribution of variable FVC % in the studied population. 
 



















Figure 22: Distribution of variable DLCO % in the studied population. 
 
Coronary Artery Disease (CAD): Categorical (Codified as 0: No, 1:Yes). 
Renal insufficiency, Serum Cr>1.2 mg/dL: Categorical (Codified as 0: No, 1:Yes). 
Radiation Dose, Gy: Continuous numerical. 
Diagnosis (NSCLC versus others): Categorical (Codified as 0: Others, 1: NSCLC). 
Survival: Continuous numerical, months. 
Pneumonia: Categorical (Codified as 0: No, 1: Yes). 
Atelectasis: Categorical (Codified as 0: No, 1: Yes). 
Postoperative pulmonary complications: Categorical (Codified as 0: No, 1: Yes). 
Stenosis: Categorical (Codified as 0: No, 1: Yes). 
Bronchopleural fistula: Categorical (Codified as 0: No, 1: Yes). 
Bronchovascular fistula: Categorical (Codified as 0: No, 1: Yes). 























































79.25 (20.44) 71.92 (20.14) 0.1246 
Coronary Artery Disease 
(CAD) 
n (%) 12 (10.17) 4 (16.00) 0.4824 
Renal Insufficiency, Serum 
Cr>1.2 mg/dL 
n (%) 3 (2.54) 2 (8.00) 0.1787 
Radiation Dose, Gy 
Mean 
(SD) 
- 57.4 (9.58)  
 
Table 14: Characteristics of the population. 
 
The mean age of the patients who underwent neoadjuvant therapy followed by sleeve 
resection was older than those who did not (Mean age 60 vs 53 years old, p<0.05) but we did 
not find any other statistically significant differences regarding the rest of the variables 
studied (BMI, FEV1 %, FVC %, Tiffeneau index, DLCO %, CAD and renal insufficiency). Among 
the patients included in the study, 4 underwent neoadjuvant chemotherapy alone, 25 
received neoadjuvant chemoradiation therapy and 114 underwent the sleeve resection 
without any neoadjuvant treatment. 84 of the patients included in the study were 
histologically diagnosed with NSCLC (84/143, 59 %), one was diagnosed with SCLC, 49 (39 %) 
underwent the sleeve resection for a carcinoid tumor and the remainder of the patients had 
a variety of histologies. For the analysis, the 4 patients who underwent neoadjuvant 




chemotherapy alone had been grouped with patients who did not receive any radiation 
therapy. 
The perioperative 30-day mortality of the series was 3.5 % (5 patients of 143), with 4 
patients in the non-neoadjuvant radiation group and 1 patient in the neoadjuvant 
chemoradiation treatment group. The overall incidence of postoperative pulmonary 
complications in the whole series was 34.26 % (49 out of 143) with significant differences 
found between the neoadjuvant chemoradiation therapy group and the other group. 21 of 
25 patients in the neoadjuvant group (84.00 %) experienced some type of postoperative 
pulmonary complications whereas 28 of 118 patients in the non-neoadjuvant radiation 
therapy group (23.73 %) experienced them (p< 0.05). Likewise, the rates of pneumonia, 
atelectasis, respiratory insufficiency, airway stenosis, prolonged air leak, incidence of 
bronchopleural fistula and need for completion pneumonectomy (6/24, 25 %) were all higher 
in the neoadjuvant chemoradiation therapy group when compared to the non-neoadjuvant 
radiation therapy group (p< 0.05, Table 15). 
Among the patients who required a completion pneumonectomy, all except for 1 were 
in the neoadjuvant chemoradiotherapy group, with radiation doses that ranged between 50 
and 68 Gy. The median overall survival of those patients who required completion 


































46 (38.98) -  
 SCLC, n (%) 1 (0.85) -  
 Other, n (%) 11 (9.32) 1 (4.00)  
     
Postoperative Pulmonary 
Complications 
n (%) 28 (23.73) 21 (84.00) <0.05 
Pneumonia n (%) 15 (12.71) 10 (40.00) <0.05 
Atelectasis n (%) 12 (10.17) 15 (60.00) <0.05 
Respiratory Insufficiency n (%) 5 (4.24) 7 (28.00) <0.05 
Prolonged Air Leak n (%) 6 (5.08) -  
     
Postoperative Airway 
Complications 
n (%) 8 (6.68) 10 (40.00) <0.05 
Stenosis n (%) 5 (4.24) 5 (20.00) 0.01 
Bronchopleural Fistula n (%) 2 (1.69) 4 (16.00) <0.05 
Completion 
Pneumonectomy 
n (%) 1 (0.85) 6 (24.00) <0.05 
     
Survival analysis     
Recurrence n (%) 19 (16.10) 15 (60.00) <0.05 
**NSCLC patients Median 62 43 0.025 
 
Table 15: Surgical outcomes. 
  




The incidence of postoperative pulmonary complications and airway complications 
was also analysed by type of resection (Tables 16 and 17), without statistically significant 
differences among them. 
 
Table 16: Postoperative pulmonary complications by type of resection (p = 0.262). 
 
 RUL: Right upper lobectomy; ML: Middle lobectomy; RLL: Right lower lobectomy; LUL: 




Type of surgery     No, n (%) Yes, n (%) Total, n (%) 
Airway resection 5 (3.50) 0 (0.00) 5 (3.50) 
RUL 44 (30.77) 8 (5.59) 52 (36.36) 
ML 14 (9.79) 0 (0.00) 14 (9.79) 
RLL 13 (9.09) 2 (1.40) 15 (10.49) 
LUL 25 (17.48) 4 (2.80) 29 (20.28) 
LLL 20 (13.99) 2 (1.40) 22(15.38) 
RN 2 (1.40) 1 (0.70) 3 (2.10) 
Bilobectomy 2 (1.40) 1 (0.70)  3 (2.10) 
 




Type of surgery     No, n (%) Yes, n (%) Total, n (%) 
Airway resection 4 (2.80) 1 (0.70) 5 (3.50) 
RUL 30 (20.98) 22 (15.28) 52 (36.36) 
ML 13 (9.09) 1 (0.70) 14 (9.79) 
RLL 11 (7.69) 4 (2.80) 15 (10.49) 
LUL 20 (13.99) 9 (6.29) 29 (20.28) 
LLL 13 (9.09) 9 (6.29) 22(15.38) 
RN 1 (0.70) 2 (1.40) 3 (2.10) 
Lobectomy 2 (1.40) 1 (0.70)  3 (2.10) 




The VIF and tolerance test did not show multicollinearity of the variables studied 
(Table 18). 
 
Variable VIF Tolerance (1/VIF) 
Age (Years) 1.37 0.73 
BMI (kg/m2) 1.16 0.87 
FEV1 % 2.40 0.42 
FVC % 2.24 0.45 
DLCO % 1.18 0.85 
CAD 1.14 0.88 
nCRT 1.19 0.83 
NSCLC 1.66 0.60 
 
Table 18: Multicollinearity among the variables included in the model (Note that a 
tolerance of 0.1 or less, equivalent to VIF of 10 or greater would have warranted further 
investigations). 
 
Logistic regression analysis showed that in our population, only age and neoadjuvant 
chemoradiation therapy were related with an increased risk of postoperative pulmonary 
complications (p= 0.046 and p= 0.01 respectively, Table 19).  













Variable Odds ratio 95 % Confidence 
interval 
p Value 
Age (Years) 1.06 0.001-0.12 0.046 
BMI (kg/m2) 0.92 -0.20-0.04 0.168 
FEV1 % 0.97 -0.18-0.11 0.658 
FVC % 1.02 -0.13-0.17 0.788 
DLCO % 1.01 -0.01-0.04 0.382 
CAD 0.62 -2.60-1.66 0.667 
nCRT 25.66 1.25-5.22 0.01 
NSCLC 0.34 -2.89-0.72 0.239 
 
Table 19:  Logistic regression model for postoperative pulmonary complications. 
 
Likewise, the logistic regression model showed that only the administration of 
chemoradiation therapy was related to an increased risk of airway complications (p=0.022, 
Table 20). 
Hosmer-Lemeshow goodness of fit for the model showed good adjustment to the 
data, with p=0.43. 
 
Variable Odds ratio 
95 % Confidence 
interval 
p Value 
Age (Years) 1.068807 .969289-1.178543 0.182 
Type of surgery .9961078 .622978-1.592722 0.987 
BMI (kg/m2) 1.030618 .8810293-1.205605 0.706 
FEV1 % .9786335 .9038942-1.059553 0.594 
FVC % .970315 .9037569-1.041775 0.406 
DLCO % .9993192 .9560094-1.044591 0.976 
CAD .6204765 .0438233-8.785083 0.724 
nCRT 17.36375 1.522785-197.9923 0.022 
NSCLC .4355181 .0155103-12.22906 0.625 
 
Table 20: Logistic regression model for airway complications. 
  




The histologic characteristics as well as the stage of studied patients with NSCLC are shown 










Carcinoma Histology   n=54 n=24   
Adenocarcinoma  n (%) 14 (23.33) 9 (37.50) 0.1884 
Squamous Cell  n (%) 38 (63.33) 14 (58.33) 0.6699 
Mucoepidermoid n (%) 4 (6.67) - - 
Neuroendocrine  n (%) 1 (1.67) - - 
Pleomorphic  n (%) 1 (1.67) - - 
Poorly Differentiated  n (%) 2 (3.33) 1 (4.17) 0.8525      
Clinical Stage         
IA n (%) 18 (30.00) 4 (16.67) 0.2093 
IB n (%) 20 (33.33) 1 (4.17) 0.0053 
IIA n (%) 11 (18.33) 2 (8.33) 0.2523 
IIB n (%) 4 (6.67) 3 (12.50) 0.3822 
IIIA n (%) 6 (10.00) 13 (54.17) 0.0011 
IIIB n (%) 1 (1.67) - - 
IV n (%) - 1 (4.17) -      
Pathology Stage         
0 n (%) - 5 (20.83) - 
IA n (%) 11 (18.33) 7 (29.17) 0.2743 
IB n (%) 12 (20.00) 2 (8.33) 0.1949 
IIA n (%) 25 (41.67) 1 (4.17) 0.0008 
IIB n (%) 3 (5.00) 2 (8.33) 0.5597 
IIIA n (%) 9 (15.00) 7 (29.17) 0.1352 
 
Table 21: Histologic and clinic-pathologic features of NSCLC patients. 
 
The overall median survival for the whole series was 157 months for the patients who 
did not receive any neoadjuvant therapy (including those with carcinoid tumors) and 43 
months for the patients who did (p= 0.000). Among patients with NSCLC the median overall 
survival was 62 months for those who did not receive neoadjuvant therapy and 43 months 
for those who received neoadjuvant chemoradiation treatment (p=0.0256, Figures 23 and 
24). 

















Figure 24: Overall median survival of the patients diagnosed with NSCLC. 
  































Despite multiple advances in NSCLC treatment, surgical resection remains the 
treatment of choice for those patients who are fit enough to undergo surgery and whose 
tumors are resectable (Ettinger et al., 2017). 
Pneumonectomy has proven to be a suitable oncologic operation for centrally located 
tumors and those affecting the airway.  However, perioperative risk (death within 30 days of 
surgery) for pneumonectomy remains as high as 7 %, almost 3 times the risk of lobectomy 
(ESTS, 2012) and quality of life is also significantly impaired (Ferguson and Lehman, 2003).  In 
previously published works, it has been shown that N0 and N1 patients who underwent sleeve 
lobectomy have better surgical outcomes when compared to patients who underwent a 
pneumonectomy (Jiménez et al., 2006).  Also, perioperative mortality risk in pneumonectomy 
is increased, being long-term (6 months) mortality risk as high as 24.7 % for right sided 
pneumonectomy patients (Rodríguez et al., 2013).  In our study of 263 patients who 
underwent a pneumonectomy, multivariate analysis showed that the laterality of the 
pneumonectomy and the presence of any cardiorespiratory complications were the main 
factors leading to death after hospital discharge (Rodríguez et al., 2013).   In another study, 
the authors proved that pneumonectomy offered worse overall survival than lobectomy or 
sleeve lobectomy in stage IB (7th Edition) (Goldstraw et al., 2007) NSCLC patients (Rodríguez 
et al., 2015).  It is true that in both cases, as they were retrospective analysis, I was not able 
to analyze the causes leading the authors to perform a pneumonectomy.  These results, 
however, and the surgical training I have received, have influenced my clinical practice and 
the practice of my faculty in Boston.  As other authors have recommended (Doddoli et al., 
2005), we have tried to avoid pneumonectomies when possible.  The Brigham and Women´s 
Hospital large volume and lung transplant experience have provided the faculty with 
extensive airway reconstruction experience. 
It is under these circumstances, while trying to avoid a pneumonectomy in centrally 
located tumors, when both neoadjuvant therapy and sleeve resections become valuable (Ma 
et al., 2016). 
Sleeve resection has become the established alternative for pneumonectomy 
regardless of the pulmonary function. Although technically more challenging, it has been 




shown that the number of pneumonectomies performed in an institution tends to decrease 
with increased surgeons’ expertise in bronchoplastic and angioplastic techniques (Martin-
Ucar et al., 2002; Gómez-Caro et al., 2011).   Sleeve resections are performed for 
approximately  5 % to 8 % of patients with resectable NSCLC (Tedder et al., 1992) but rates as 
high as 13 % have also been published (Okada et al., 2000; Gómez-Caro et al., 2011). 
The perioperative mortality and morbidity after sleeve resection has been shown to 
be better than in pneumonectomy, with significantly improved quality of life, even in the 
elderly (Yoshino et al., 1997; Okada et al., 2000; Ferguson and Lehman, 2003; Ma et al., 2007; 
Bölükbas et al., 2010; Schirren et al., 2011). In recent studies the perioperative mortality of 
sleeve resection ranged from 2 % in the series of Merritt et al (Merritt et al., 2009) to 4.1 % in 
the studies by Ferguson et al (Ferguson and Lehman, 2003) and Yildizeli et al (Yildizeli et al., 
2007).  In a meta-analysis published in 2012 by Shi et al (Shi et al., 2012), sleeve resection 
patients had lower mortality when compared with pneumonectomy patients with similar 
morbidity and locoregional recurrence rates.  Furthermore, sleeve lobectomy patients had a 
better overall survival, less loss of pulmonary function and better quality of life than 
pneumonectomy patients did. 
On the other hand, it seems clear that neoadjuvant therapy benefits patients and 
improves survival in stage IIIA and some IIIB situations (mediastinal downstaging and tumor 
shrinkage allowing for parenchyma sparing operations) with careful selection of surgical 
candidates (Thomas et al., 2008; Albain et al., 2009; Cerfolio et al., 2009). 
Several studies have shown the feasibility and the safety of sleeve resection after 
neoadjuvant treatment (Burfeind et al., 2005; Bagan et al., 2009; Milman et al., 2009; Gómez-
Caro et al., 2012), although other authors found opposite results (Rea et al., 2008), specifically 
after neoadjuvant radiotherapy (Hampel et al., 2010). These adverse results have been 
attributed most of the time to the effects that neoadjuvant treatment, specifically radiation, 
has on the blood supply, directly affecting the bronchial anastomotic healing (Yamamoto et 
al., 2000; Hampel et al., 2010). 
In our study, the perioperative mortality observed among patients who underwent 
sleeve resection was 3.5 % (3 % among patients without neoadjuvant radiation treatment and 
4 % in the patients with neoadjuvant chemoradiotherapy treatment), comparable to the rates 
reported in the literature.  As expected and supported by the evidence of radiotherapy 




impairing bronchial healing, most of the airway complications and the completion 
pneumonectomies occurred among the patients treated with neoadjuvant chemoradiation 
therapy.  
Data in the literature studying specifically the incidence of postoperative pulmonary 
complications after sleeve resections are minimal, but our results can be compared to those 
obtained by Rea et al (Rea et al., 2008) and Doddoli et al (Doddoli et al., 2005) in their series.  
Although coronary artery disease, FEV1 %, FVC %, DLCO % and renal insufficiency have 
already been proved to be directly related with the incidence of complications after major 
anatomical lung resections (Brunelli et al., 2010; Ferguson et al., 2014; Brunelli et al., 2015), 
in our population only the age and the administration of neoadjuvant chemoradiation therapy 
were related with an increased risk of postoperative pulmonary complications and only the 
administration of neoadjuvant therapy was related with an increase in airway complications. 
The minimal impact of coronary, pulmonary, and renal diseases may be related to the ability 
to identify these problems and improve them pre-operatively at the Brigham and Women’s 
Hospital. 
Furthermore, in order to try to control the possible confounders related to the 
preoperative risk factors and to obtain the most accurate results in the logistic regression 
model, we chose the ‘manual method’ to introduce the independent variables, keeping in the 
model all those clinically relevant variables that could have a negative impact in outcomes 
after pulmonary resection. We did so because after estimating multicollinearity of the 
variables with the VIF and tolerance tests they did not show any correlation among them 
(Mansfield and Helms, 1982). 
Whether or not the effect of neoadjuvant chemoradiation was related to the 
combination of both chemotherapy and radiation or radiation alone, could not be determined 
in our study, as all the patients treated with radiotherapy received it in combination with 
chemotherapy and only 4 patients received chemotherapy alone.  Based on Yildizeli et al 
(Yildizeli et al., 2007) and Hampel et al (Hampel et al., 2010) studies, we could hypothesize 
those results are secondary to the effects induced by radiation therapy, but our data does not 
allow that analysis. 




It is remarkable that the incidence of postoperative pulmonary complications and 
airway complications among our neoadjuvant therapy patients is consistently higher than 
those already reported (Rendina et al., 1997; Veronesi et al., 2002; Massard, 2009) being 
notable for a 25 % of completion pneumonectomy rate.  This may be related to an institutional 
bias in favor of radiation doses near 54 Gy in the neoadjuvant setting. 
Although multimodality treatment can have deleterious effects on the patients, 
before, during and after the operation, we have not been able to find an objective explanation 
for the 84 % complication rate among the neoadjuvant chemoradiotherapy Brigham patients.  
One explanation of this fact could be the meticulously defined and prospectively recorded 
Brigham database of complications and adverse events.  The Division of Thoracic Surgery has 
advocated aggressively identifying minor and moderate complications to prevent 
postoperative deaths.    
When analyzing the completion pneumonectomy rate within the Brigham series, I 
have sought out similar experiences by other authors.  Although airway complications are not 
a systematically reported outcome in the literature, some authors have similar rates of 
completion pneumonectomy when trying to solve airway problems or treat complex 
bronchopleural fistulas (Rea et al., 2008). 
In this series, the incidence of bronchopleural fistula was 4.19 %, similar to those rates 
already reported (Kutlu and Goldstraw, 1999; Ludwig et al., 2005; Yildizeli et al., 2007; Merritt 
et al., 2009).  Some authors (Rendina et al., 2002) have shown that pedicled flaps may have 
an important role in reducing the incidence of airway complications but, in the Brigham 
practice, bronchial anastomosis coverage depends on attending preferences and includes 
pleura, azygous vein, pericardium and pericardial fat pat.  As it is an inconsistent and a very 
heterogeneous variable, I decided to exclude it from this study.   
Different authors consider the protection of the bronchial anastomosis with a pedicled 
flap a mandatory part of the operation (Yildizeli et al., 2007).  Others do not perform it 
routinely, even after high doses of radiation (Storelli et al., 2012).  Even with pedicled flaps, 
the rates of reported bronchopleural fistula range from 2 % to 6.9 % (Ludwig et al., 2005; 
Yildizeli et al., 2007; Merritt et al., 2009).  Kutlu et al (Kutlu and Goldstraw, 1999), in their 
series of 100 cases, gave more importance to the careful handling of the airway and the 
preservation of the peribronchial tissue than to wrapping the anastomosis.  In their series, 




without any protection of the bronchial anastomosis, Konstantinou et al (Konstantinou et al., 
2009) did not register any airway complications.  Moreover, the incidence of airway 
complications after lung transplantation has not been affected by wrapping the anastomosis 
with omentum or internal mammary pedicled flaps (Khaghani et al., 1994; Weder et al., 2009). 
When explaining the limited overall survival of patients who received neoadjuvant 
chemoradiation treatment in our series, it is difficult to determine if it is secondary to the 
increased complications after neoadjuvant therapy or to the inclusion of advanced stages of 
NSCLC. 
The long-term results and local control after sleeve resection are still a matter of 
debate.  Reported 5-year survival rates for sleeve resection in N1 patients range from 0 to 64 
% (Van Den Bosch et al., 1981; Deslauriers et al., 1986; Van Schil et al., 1991), very similar to 
the results observed in this series.  This heterogeneity has been related to different 
intraoperative techniques for staging and resection (Veronesi et al., 2002).  No statistically 
significant differences were found in survival and recurrence in N0 and N1 patients when 
systematic lymphadenectomy was performed (Deslauriers et al., 1986; Van Schil et al., 1991; 
Mehran et al., 1994).  Likewise, no differences in overall survival were found between 
pneumonectomies and sleeve lobectomies (Weisel et al., 1979; Okada et al., 2000).  Even with 
disappointing survival reported in N2 patients after sleeve lobectomy (Naruke, 1989; Mehran 
et al., 1994), it would have been difficult to achieve better results with a pneumonectomy, as 
the main pattern for recurrence were distant metastases (Naruke, 1989; Kumar et al., 1996). 
Local recurrence has been another concerning factor after sleeve lobectomy and, 
although not included in my analysis, it ranges from 4 % (Deslauriers et al., 1986) to 42 % 
(Rendina et al., 1999) in extended resections.  Although Tedder at al (Tedder et al., 1992) 
reported higher local recurrence after sleeve lobectomy (12.5 %) than after sleeve 
pneumonectomies (4 %), this information remains difficult to interpret as most of the authors 
did not specify what the site of recurrence was.   
Unfortunately, although this thesis analyzes one of the largest series of sleeve 
resections after neoadjuvant treatment, the number of patients included remains small, 
making it difficult to draw definitive treatment recommendations on this group of surgical 
candidates.  The heterogeneity of the population, the different neoadjuvant therapy 
regimens, as well as the technical aspects of a challenging surgical procedure could have 




affected the results obtained.  The lack of pneumonectomy patients within the chosen dataset 
has made it impossible to compare the outcomes between the resections. 
The lack of analysis by NSCLC stage could have played a role as a confounding factor 
when analyzing the overall survival.  Due to the limited number of patients studied, we were 
not able to determine if the decreased overall survival in this subset of patients is related to 
the effects of the neoadjuvant treatment or to an advanced pathological stage. Further 
analysis with a larger number of patients included is required to help illuminate this matter.   
Such an analysis might require pooling of large datasets from multiple institutions. 
The analysis of this dataset leads us to conclude that selection and preoperative 
preparation of patients appears to be satisfactory.  Details of the operative technique might 
be improved if it led to less airway complications.  Aggressive pulmonary toilet 
postoperatively, including bronchoscopy where indicated, is a necessary part of patient care.  
Despite these limitations, this analysis provides new insight that might affect treatment 
paradigms.  For instance, a multimodality treatment option that might be considered could 
be neoadjuvant chemotherapy followed by surgery, then chemoradiation in the adjuvant 
























9. CONCLUSION AND CLOSING REMARKS










CONCLUSION AND CLOSING REMARKS: 
In conclusion: 
1. In this population of patients submitted to sleeve lung resection, I have 
shown that the administration of neoadjuvant therapy, probably 
radiotherapy, has a negative impact in the incidence of both respiratory 
complications and airway complications.   
 
2. It is remarkable to note a 25 % risk of completion pneumonectomy to treat 
airway complications among those patients who received neoadjuvant 
chemoradiation therapy in a high surgical volume center.   
 
3. Although we have not been able to conclude the causative effect of 
neoadjuvant chemoradiation therapy or of the advanced stage at the time 
of the resection, the patients who required a sleeve resection after 
neoadjuvant treatment suffered a significantly decreased overall survival 
when compared to those who did not require neoadjuvant chemoradiation 
therapy. 
 
4. Considering these results, careful consideration of neoadjuvant 
chemoradiation treatment in those patients who are surgical candidates 
but who might require a sleeve resection at the time of the operation, 
should be made.  
 
5. In case neoadjuvant treatment cannot be avoided, mediastinal restaging 
and detailed discussion of the increased perioperative risk of complications 
becomes mandatory.   
 
6. Furthermore, extreme care should be paid to the surgical technique and 
directed perioperative strategies to avoid respiratory complications such 
as intensive chest physiotherapy and aggressive pulmonary toilet in order 
to improve the outcomes of this subgroup of patients. 



















10. RESUMEN DE LA TESIS














Las resecciones broncoplásticas son una alternativa válida a la neumonectomía en 
pacientes con carcinoma de pulmón no microcítico resecable cuando éste se encuentra en la 
proximidad de la vía aérea.  Aunque han demostrado su equivalencia a la neumonectomía en 
lo que a control local y a distancia de la enfermedad se refiere, debido a su naturaleza y a su 
mayor complejidad técnica, continúa debatiéndose si la incidencia de complicaciones 
pulmonares postoperatorias y de la vía aérea, especialmente tras la administración de 
tratamiento neo-adyuvante con quimio y radioterapia, es mayor que en aquellos pacientes 
que no reciben tratamiento neo-adyuvante.  
Algunos estudios han demostrado el impacto negativo de la radioterapia sobre la 
circulación bronquial, lo que influye directamente en la cicatrización de las anastomosis, 
mientras que otros, en su mayoría con un número pequeño de pacientes, no han sido capaces 
de encontrar diferencias. 
  
b) Estado actual del tema: 
La administración de tratamiento neo-adyuvante con quimio y radioterapia ha 
demostrado ser una opción aceptable en aquellos pacientes con carcinoma de pulmón no 
microcítico de localización central o localmente avanzado que pueden tolerarlo. 
Consideración especial requieren aquellos pacientes que pueden necesitar una 
neumonectomía o una resección broncoplástica para su tratamiento definitivo, ya que 
este tratamiento, especialmente la radioterapia, puede presentar efectos deletéreos en 
la cicatrización de la sutura bronquial.   
 
c) Hipótesis: 
La administración de tratamiento neo-adyuvante con quimio y radioterapia en 
pacientes que van a ser sometidos a una resección pulmonar broncoplástica aumenta la 
incidencia de complicaciones pulmonares postoperatorias, así como de complicaciones 




de la vía aérea y estas complicaciones podrían tener un efecto negativo en la 
supervivencia a largo plazo de este grupo de pacientes. 
 
d) Objetivos: 
1. Analizar la asociación entre la incidencia de complicaciones pulmonares y de la vía 
aérea postoperatorias en pacientes sometidos a resección pulmonar broncoplástica 
con la administración de tratamiento neo-adyuvante con quimio y radioterapia.  
 
2. Analizar si estas complicaciones se relacionan negativamente con la supervivencia de 
estos pacientes. 
 
e) Material y métodos: 
Hemos estudiado una cohorte prospectiva de 143 pacientes sometidos a resección 
pulmonar broncoplástica en Brigham and Women´s Hospital entre Enero de 1998 y Diciembre 
de 2016. Se ha considerado como exposición la administración de tratamiento neo-adyuvante 
antes de la resección pulmonar. Toda la información se obtuvo de una base de datos 
prospectiva con doble control de calidad de los datos introducidos.  
Tras analizar la distribución de las variables objeto de estudio en la muestra y tras 
descartar colinearidad entre ellas mediante el cálculo de VIF (Variable Inflation Factor) y 
Tolerancia, se diseñó un modelo de regresión logística para cada tipo de complicaciones. Las 
variables dependientes consideradas en cada modelo fueron la incidencia de complicaciones 
pulmonares postoperatorias y la incidencia de complicaciones de la vía aérea, 
respectivamente.  
Se definieron las complicaciones pulmonares postoperatorias como la incidencia de 
atelectasia pulmonar que requiriera broncoscopia, neumonía o ambas. 
Las complicaciones de la vía aérea incluyen estenosis que requiriera dilatación, fístula 
bronco-pleural, fístula bronco-arterial y la necesidad de completar la neumonectomía por 
cualquier problema relacionado con la anastomosis. 
Las variables independientes introducidas en cada modelo fueron: Edad, BMI, FEV1 %, 
FVC %, DLCO %, la presencia de enfermedad coronaria, diagnóstico de carcinoma de pulmón 
no microcítico y la administración o no de tratamiento neo-adyuvante.  




Posteriormente se calculó la supervivencia de toda la serie y de los pacientes 
diagnosticados de carcinoma de pulmón no microcítico. Se estimaron las diferencias en la 
supervivencia mediante el test log rank. 
Todos los cálculos se realizaron utilizando STATA/IC 15. 
 
f) Resultados: 
En total se analizaron 143 pacientes que se sometieron a resección pulmonar 
broncoplástica en nuestra Institución. Los pacientes que recibieron tratamiento neo-
adyuvante eran mayores que los que no lo recibieron (Media: 60 años frente a 53, p < 0,05), 
pero no encontramos diferencias estadísticamente significativas en el resto de las variables. 
84 de los 143 pacientes estudiados presentaron el diagnóstico de carcinoma de pulmón no 
microcítico, 1 fue diagnosticado con carcinoma microcítico, 49 con tumores carcinoides y el 
resto con histologías variadas. 
La mortalidad a 30 días de la serie fue 3,5 % (5 pacientes de 143). La incidencia de 
complicaciones pulmonares postoperatorias en toda la serie fue 34,26 % (49 pacientes), con 
diferencias estadísticamente significativas entre el grupo de pacientes que recibió 
tratamiento neo-adyuvante y el que no lo recibió (84,00 % de complicaciones entre los 
pacientes que recibieron quimio y radioterapia neo-adyuvante frente a 23,73 % entre los que 
no la recibieron, p <0,05). 
Así mismo, la incidencia de neumonía, atelectasia, insuficiencia respiratoria, estenosis 
de la vía aérea, fístula bronco-pleural y necesidad de completar la neumonectomía (6/24) 
fueron mayores entre los pacientes que recibieron tratamiento neo-adyuvante (p<0,05). 
Los pacientes que requirieron completar la neumonectomía se encontraban, excepto 
1, en el grupo de tratamiento neo-adyuvante, con dosis de radioterapia que iban desde los 
50 hasta los 68 Gy. 
La mediana de supervivencia de los pacientes que requirieron completar la 
neumonectomía fue de 28 meses (Rango: 7 a 130 meses, media: 38,57 meses, SD: 41,35). 
Tras el análisis de regresión logística, solo la edad y la administración de tratamiento 
neo-adyuvante se relacionaron con un aumento de las complicaciones pulmonares 




postoperatorias (p= 0,046 y p= 0,01 respectivamente, Hosmer-Lemeshow test de bondad de 
ajuste del modelo: p=0,84). 
De la misma manera, otro modelo de regresión logística demostró que solo la 
administración de tratamiento neo-adyuvante se relaciona con el aumento en la incidencia 
de complicaciones de la vía aérea (p=0,022, Hosmer-Lemeshow test de bondad de ajuste del 
modelo: p=0,43). 
La mediana de supervivencia de toda la serie fue 157 meses en los pacientes que no 
recibieron tratamiento neo-adyuvante (incluyendo aquellos con tumores carcinoides) y 43 
meses para los pacientes que sí lo recibieron (p=0,000). Entre los pacientes diagnosticados 
con carcinoma de pulmón no microcítico, la mediana de supervivencia fueron 62 meses para 
aquellos pacientes que no recibieron tratamiento neo-adyuvante y 43 meses para aquellos 





















































1. En este grupo de pacientes sometidos a resección pulmonar 
broncoplástica, la administración de terapia neo-adyuvante, 
probablemente radioterapia, supone un impacto negativo tanto en la 
incidencia de complicaciones pulmonares como en la incidencia de 
complicaciones de la vía aérea.  
 
2. En esta serie procedente de un centro de alto volumen quirúrgico y con un 
programa consolidado de trasplante pulmonar, la necesidad de completar 
una neumonectomía para tratar las complicaciones de la vía aérea es de 
hasta un 25 % en los pacientes que recibieron quimio y radioterapia neo-
adyuvantes.  
 
3. Aunque no hemos sido capaces de diferenciar si se debe a la terapia neo-
adyuvante en sí o a un estadio oncológico avanzado en el momento del 
diagnóstico, los pacientes que recibieron tratamiento neo-adyuvante 
presentan una menor supervivencia cuando se comparan con los que no lo 
recibieron.  
 
4. Estos resultados apoyan la evaluación cuidadosa de la administración de 
quimio y radioterapia neo-adyuvantes en todos aquellos pacientes que 
sean candidatos a una resección en manguito.  
 
5. Cuando el tratamiento neo-adyuvante sea estrictamente necesario y 
teniendo en cuenta tanto los resultados que presentamos aquí como los 
presentados anteriormente por otros autores, debe llevarse a cabo una re-
estadificación mediastínica sistemática.  
 
6. Dado el mayor riesgo postoperatorio que presentan estos pacientes, su 
discusión en comités multidisciplinares ha de ser obligatoria, así como una 
técnica quirúrgica especialmente cuidadosa y la implementación de 




estrategias postoperatorias como la fisioterapia respiratoria para prevenir 
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APPENDIX 2: LIST OF ABBREVIATIONS: 
NSCLC: Non small cell lung cancer. 
FEV1 %: Forced expiratory volume in the first second. 
FVC %: Forced vital capacity. 
CT: Computed tomography. 
PET-CT: Positron emission tomography–computed tomography. 
EBUS: Endobronchial ultrasound. 
DCLO %: Diffusing or transfer factor of the lung for carbon monoxide. 
PEEP: Positive end-expiratory pressure. 
ECMO: Extracorporeal membrane oxygenation. 
QoL: Quality of life. 
EORTC: European Organization for Research and Treatment of Cancer. 
PF: Physical function. 
SF: Social function. 
RF: Role function. 
GH: General Health. 
CF: Cognitive function. 
PCS: Physical composite score. 
Shoulder dysf: Shoulder dysfunction. 
QALY: Quality-adjusted life-year. 
CAD: Coronary artery disease. 
RI: Renal insufficiency. 
BMI: Body mass index. 
TICU: Thoracic intermediate care unit. 
       RUL: Right upper lobectomy. 
       ML: Middle lobectomy. 
       RLL: Right lower lobectomy. 
       LUL: Left upper lobectomy. 
       LLL: Left lower lobectomy. 
       RN: Right pneumonectomy. 




nCRT: Neoadjuvant chemo-radiation therapy. 
VIF: Variance inflation factor. 
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